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ABSTRACT OF DISSERTATION
MAST CELLS AS NOVEL EFFECTOR CELLS IN THE PATHOGENESIS OF
CHRONIC GRAFT-VERSUS-HOST DISEASE
Hematopoietic stem cell transplantation (HSCT) is most commonly a treatment for
inborn defects of hematopoiesis or acute leukemias. Widespread use of HSCT, a potentially
curative therapy, is hampered by onset of graft-versus-host-disease (GVHD), a condition
wherein the donor cells recognize the patient tissues as non-self. GVHD can manifest
anywhere from weeks to decades post-transplant and is classified as either acute or chronic
GVHD, both of which are significant causes of transplant-related morbidity and mortality.
However, GVHD is a complex, multifactorial, and enigmatic disease. The factors
driving GVHD at the cellular and molecular level are incompletely understood.
Immunosuppression targeting T-cells has not always been effective and increases the risk
of relapse. Prophylactic immunosuppression can be particularly detrimental in the context
of cGVHD, where symptoms can appear even decades after transplant. There is great need
to further understand the mechanisms of GVHD pathogenesis in order to more effectively
make use of HSCT.
Mast cells are an arm of the immune system that are primarily known for their role
in atopic disease. However, recent studies have demonstrated new paradigms for mast cell
activity, showing that they can play important roles in tissue homeostasis and wound
healing. Therefore, the purpose of this dissertation is to explore the role of mast cells in the
onset of fibrotic chronic GVHD. We hypothesized that mast cells, through their
interactions with tissue-resident and circulating GVHD effector cells, would be detrimental
in chronic GVHD by exerting proinflammatory and profibrotic effects on the surrounding
tissue. We examined mast cells in vitro in mono- and co-culture models, finding that they
are significantly resistant to conditioning-induced cell death, as well as capable of inducing
proliferation of fibroblasts. We further tested our hypothesis in vivo in murine models of
allogeneic transplant using both wild type and mast cell-deficient mice. Compared to wild
type recipients, mast cell-deficient recipients had significant reductions in GVHD
symptomology and skin manifestations, as well as in chemokine levels and immune cell
recruitment in the skin. We show that mast cell chemokine production is blocked by drugs
currently used clinically to treat chronic GVHD, and that skin from GVHD patients is
enriched in mast cells. Lastly, we show that recipient-derived mast cells are capable of
surviving after transplant.
Taken together, these data demonstrate a role for mast cells in the onset of dermal
chronic GVHD. We therefore outline methods and pathways by which mast cells could be
targeted for therapeutic inhibition and discuss future studies that would further clarify the
function of mast cells in chronic GVHD pathogenesis.
KEYWORDS: GVHD, mast cells, transplant, immunology
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CHAPTER 1. INTRODUCTION AND BACKGROUND
1.1

Introduction
Hematopoietic stem cell transplantation (HSCT) is most commonly a treatment for

inborn defects of hematopoiesis or acute leukemias. Widespread use of HSCT, a potentially
curative therapy, is hampered by the development of graft-versus-host-disease (GVHD), a
condition wherein the donor cells recognize the patient tissues as non-self, leading to
dysregulated inflammation. GVHD can manifest anywhere from weeks to decades posttransplant and is classified as either acute (aGVHD) or chronic GVHD (cGVHD), both of
which are significant causes of transplant-related morbidity and mortality. Acute and
chronic GVHD are complex, enigmatic diseases, displaying a variety of symptomology
including facets that resemble autoimmune, chronic inflammatory, and atopic immune
responses.
However, acute and chronic GVHD are complex, multifactorial, and enigmatic
diseases. The factors driving either form of GVHD at the cellular and molecular level are
incompletely understood. While alloreactive T-cells are often considered to drive much of
acute GVHD symptomology, immunosuppression targeting T-cells has not always been
effective and increases the risk of relapse. Prophylactic immunosuppression can be
particularly detrimental in the context of cGVHD, where symptoms can appear even
decades after transplant. In chronic GVHD, both donor and recipient immune cells can
participate in excessive and prolonged inflammation, causing organ damage. There is great
need to further understand the mechanisms of GVHD pathogenesis in order to more
effectively make use of HSCT.
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Mast cells are an arm of the immune system and are primarily known for their role
in atopic disease. However, recent studies have demonstrated new paradigms for mast cell
activity, showing that they can play important roles in tissue homeostasis and wound
healing. In chronic graft-versus-host disease (cGVHD), aberrant wound healing
mechanisms lead to pathological fibrosis across multiple organs, but the cellular etiology
driving fibrosis is not well-understood. Even outside the context of GVHD, pathogenic
fibrosis is incredibly common in the developed world, with up to 45 percent of all deaths
associated with symptoms of chronic fibrosis1, making it a major public health concern and
demonstrating the urgent need to better understand the mechanisms involved.
Therefore, the purpose of this dissertation is to explore the role of mast cells in the
onset of fibrotic chronic GVHD. We hypothesized that mast cells, through their
interactions with tissue-resident and circulating GVHD effector cells, would be detrimental
in chronic GVHD by exerting proinflammatory and profibrotic effects on the surrounding
tissue. In addition, we explored therapeutic options for inhibiting mast cell responses in
cGVHD and investigated the survival and donor-versus-recipient origin of mast cells in the
post-transplant environment.

1.2

Skin – Structure and function
The skin is the most commonly affected organ in cGVHD. It is also the largest

organ in the body, with a weight of 8-10 pounds and surface area of 22 square feet in an
average adult2. The skin is a physical barrier acting as the first line of defense against many
infections or injuries. Since its surface is directly exposed to the environment, it is also
2

highly susceptible to environmental insults. Skin is also highly visible as an external
marker of health, and disfiguring skin diseases or conditions often lead to social shaming
or stigmas that can negatively affect an individual’s mental or physical health.
These factors weigh heavily into the structure and function of the skin; its ultimate
function is to maintain a homeostatic environment between the external world and the rest
of the body3. As a barrier, it needs to restrict access to the rest of the body. As the most
exterior organ, it needs to be able to signal its health and to regenerate when it is damaged.
It needs to be able to summon a sufficient immune response to fight off infections that may
be present.
As we all learn when getting a scrape at a young age, skin is multi-layered. The
outermost layer, or epidermis, consists of several layers of functionally differentiated cells.
Most exterior is the stratum corneum, followed by the strata lucidum, granulosum,
spinosum, and basale. The epidermis itself has no blood vessels, being reliant on diffused
oxygen from the outside environment and from the underlying tissues. Each stratum is
composed of cell bodies between one and twenty layers thick, depending on the stratum in
question. Cells are formed at the basale layer and migrate outward, gradually changing
function and producing additional keratin as they move. Because of this migration, capping
the stratum corneum are several dozen layers of dead, highly keratinized cells that act as
the outermost layer2.
Underneath the epidermis is the dermis. The two are connected by a strong
basement membrane, and the dermis contains hair follicles, sebaceous glands, lymphatic
vessels, and many of the nerve endings in the skin. The dermis is vascularized, and
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therefore also supplies nutrients to the lower layers of the epidermis. Collagen deposition
by fibroblasts usually occurs here, and dermal thickening is a hallmark of many cutaneous
fibrotic diseases4. Immune cells that enter the skin migrate from the lymphatic or blood
vessels in the dermis, then transit to the appropriate location for their function.
In addition to migratory cells, the skin contains tissue-resident cells such as
Langerhans cells, macrophages, mast cells, and certain subsets of T-cells. These cells serve
to patrol the local environment, looking for tissue damage or pathogens. Therefore, the
tissue-resident immune cells act as sentinel cells engaged in maintaining a tissue integrity.
This can consist of environmental sampling by Langerhans cells or wound healing,
elimination of local infections, and recruitment of systemic immunity by macrophages and
mast cells5.
The dermis is also a site of fibrosis. Fibroblasts live in the dermis and are activated
by local or systemic triggers, inducing myofibroblast differentiation, proliferation, and
collagen deposition, often as a mechanism of wound healing and tissue repair. However,
when this occurs in the context of chronic inflammation, dysregulation of these wound
healing responses can occur, leading to dermal thickening by excessive collagen6.

1.3

Hematopoietic stem cell transplantation
Hematopoietic stem cell transplantation, or HSCT, is a procedure in which a patient

undergoes conditioning to ablate or destroy their bone marrow, followed by introduction
and engraftment of hematopoietic stem cells from a donor. This results in replacement of

4

the patient marrow with donor cells, creating a chimera wherein the hematopoietic system
is derived from the donor, while the non-hematopoietic cells and tissues remain host
derived. This is used as a treatment for a defective hematopoietic system, especially in the
context of lymphoma, myeloma, or acute and some chronic leukemias. It can also be used
for inborn defects of hematopoiesis such as aplastic anemia, sickle cell disease, or some
metabolic disorders.
1.3.1

Procedure
The first step for any HSCT procedure is ensuring the patient is fit enough and

willing to undergo transplant7. This must be a decision made between the patient and the
care provider, all the while ensuring that there is an understanding of the patient’s
underlying disease, comorbidities, chronic viral infection status, type of transplant,
resources of the healthcare center and the home environment, and likely adherence to posttransplant regimens. The patient, meanwhile, needs to come to recognize the risks and
benefits associated with this treatment, and to be educated on transplant terminology that
is very likely foreign to them. Patient age and functional status must be assessed by the
physician; under certain conditions, elderly patients or those with poor organ function may
be viably transplanted, or they may be candidates only for mild transplant regimens or
alternatives to transplant. This decision is very multifactorial and patients are subject to an
extensive pre-transplant workup and physical assessment8.
Once the decision has been made to move ahead with transplant, either the patient’s
own hematopoietic cells will be utilized (autologous transplant) or a suitable donor must
be found. This is most often from an HLA-matched (related or unrelated) allogeneic donor,
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and less frequently from a mismatched unrelated donor, from a parent or child (a
haploidentical transplant) or using cord blood. The HLA system, coding for the major
histocompatibility complex (MHC) in humans, is generally responsible for self vs. nonself differentiation via positive and negative selection of the developing T-cell repertoire
in the thymus. THe HLA system is also critical to identify a potential hempatoietic stem
cell donor. Donor matching is based on the HLA genes, consisting of HLA-A, -B, -C,
DRB1, DQB1 and increasingly DP9. The level of genetic and phenotypic diversity can
make it difficult to find a fully patient-matched donor for allogeneic transplants. Donor
matching is based on the type of transplant recommended by the patient’s care team as well
as the timeline in which a transplant is needed10. Matching a patient with a donor is usually
performed through public registries such as “Be The Match”, which is operated by the
National Marrow Donor Program.
Donor stem cell source can be another complex decision. In the past, whole bone
marrow extracted from the iliac crest of the donor was used. Much more commonly today,
the donor is treated with granulocyte colony stimulating factor (G-CSF), which mobilizes
stem cells from the marrow into the peripheral blood. These stem cells are then collected
and concentrated by apheresis, and this product is used for infusion. Umbilical cord blood
can also be a source of stem cells, though this is not always an option. The stem cell source
has been shown to sometimes lead to differences in overall transplant outcome.
After a donor has been identified that will be suitable for the current indication,
risks and benefits have been assessed and reviewed with the patient the patient will then
undergo pre-transplant conditioning. This is usually separated into myeloablative (MA),
reduced-intensity conditioning (RIC), or nonmyeloablative (NMA) conditioning.
6

Conditioning is performed with either alkylating agents, total body irradiation (TBI), or a
combination of the two; RIC regimens usually reduce the dosage by 30 percent or more.
Historically, high-dose conditioning was the standard of care, but in recent years RICbased and NMA regimens have become more common, allowing physicians to offer
allogeneic HCT to older and frailer patients as well. Commonly used chemotherapeutic
agents include busulfan, cyclophosphamide, fludarabine, AraC, and melphalan, among
others. TBI is used most often as a fractionated dose, with a final exposure of 12-16 Gy for
high-dose conditioning, or 2-6 Gy for RIC and NMA11.
Post-conditioning, patients are infused with the donor stem cells. Blood counts are
monitored daily for engraftment (as measured by neutrophil and platelet counts in
peripheral blood). Once the clinical team is sure of engraftment, the patient can most often
be safely discharged and monitored as an outpatient7.

1.3.2

HSCT Subtypes
HSCT has two main subtypes: autologous and allogeneic. In an autologous

transplant, hematopoietic stem cells are extracted from the patient and cryopreserved, then
after conditioning, the extracted bone marrow is re-engrafted into the patient. A rarer type
of transplant, syngeneic HSCT, uses bone marrow donated from an identical twin, and is
rarely used clinically, but is used extensively in murine models due to genetic matching
between littermates12. In both autologous and syngeneic transplants, there is no selfreactivity and little-to-no GVHD since the cells are derived from a genetically identical
source. Autologous transplants still carry risk, though better conditioning regimens and
7

post-transplant care have allowed for the use of autologous transplants even in an outpatient
setting13.
In contrast, allogeneic transplants (allo-HSCT), comprising greater than 40 percent
of all HSCT procedures, are transplants from a related or unrelated HLA-compatible donor
(either fully or partially HLA-matched, haploidentical, or cord blood)14. These transplants
run the risk of graft-versus-host disease, but also greatly reduce relapse rates through posttransplant immunosurveillance by donor cells. Fully or partially HLA-matched transplants
are most common, although haploidentical transplants are recently becoming an option for
more patients. In large part this is due to the use of post-transplant cyclophosphamide,
which helps to prevent alloreactive clones from expanding15,16.

1.3.3

Indications
Most HSCTs are performed as a treatment for hematologic malignancy.

Autologous transplants are used most commonly for lymphomas and multiple myeloma13.
Allogeneic transplants often present the only chance of cure17, yet sometimes are
seen as a double-edged sword. More than 24,000 allogeneic HSCTs are carried out
annually. 72% of all allo-HSCTs are performed on patients with leukemia, with AML alone
accounting for more than half of all allogeneic transplants. Allogeneic HSCT can also be
performed for treatment of inborn defects of hematopoiesis or some metabolic disorders.
For patients with diseases such as severe aplastic anemia, thalassemia, or peroxisomal
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storage disorders, allogeneic HSCT can offer hope of a cure; the donor blood-forming
system would ideally completely supplant the defective host system18,19.
Especially in older patients, HSCT is often overlooked as first-line therapy in many
diseases, although it is being increasingly considered with RIC regimens and haploidentical
transplants offering additional options for patients and healthcare providers11. In AML,
where the patient population is elderly and often impacted with severe disease, many
treatment strategies are viewed as a “bridge to transplant,” where the goal is to get the
disease burden under control while keeping the patient sufficiently healthy to undergo
allogeneic HSCT20. The recent glut of FDA approved treatments for AML allows doctors
more choice as to how to bridge a patient to transplant most effectively21.

1.3.4

Donor vs. recipient paradigm
Of great importance in the discussion of HSCT and GVHD is the paradigm of donor

(or “graft-derived”) versus recipient (or “host-derived”) cells. The idea behind the
conditioning phase prior to HSCT is to greatly reduce or entirely eliminate immune cells
and bone marrow from the recipient. This allows for engraftment of the donor stem cells
to the marrow, where they take up the burden of hematopoiesis. However, the cells in the
organs, tissues, etc., are non-hematopoietic in origin and do not derive from the bone
marrow.
Therefore, after a successful allogeneic HSCT, a patient will be a chimera wherein
the immune and blood-forming system has reconstituted from the donor stem cells, while
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the non-hematopoietic cells will be derived from the host. Some host-derived immune
cells, especially some tissue-resident cells and APCs, are considered to survive the
conditioning phase. As will be discussed later in this dissertation, we also have strong
evidence supporting mast cell survival after conditioning as well. These recipient-derived
cells often play a key role in initiation of GVHD through their cross-talk with donorderived cells.

1.3.5

Elimination of residual host-derived cells and graft-versus-leukemia
One manifestation of graft-versus-host reactivity is alloreactive elimination of host-

derived cells22. After HSCT, many of the immune cells coming out of the marrow go
through some degree of positive and negative selection, a process that minimizes
alloreactivity. However, in GVHD this process can often go awry, with thymic dysfunction
leading to defective negative selection of T-cells, allowing for alloreactive clones to exit
the thymus23. Additionally, alloreactive B-cells can be stimulated by IL-4, IL-13, and IL21 produced by both host and donor cells, which stimulates germinal center formation and
antibody production24. This can lead to the donor immune system developing reactivity
against self-antigens expressed on host cells.
While GVHD primarily targets tissues, residual immune cells can also be
eliminatedby donor-derived T-cells. Alternatively, autoantibodies can target host cells and
tissues, which can trigger their elimination by various methods, depending on the isotype
of antibody being produced. Donor-derived NK cells, while substantial effectors of the
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GVL effect, can also target residual cells based on the degree of mismatch in MHC class I
between the donor and host25.
Alloreactive elimination of recipient cells has been proven to be beneficial when
it relates to residual or recurrent cancer cells. Even in the context of a fully MHC-matched
transplant, minor histocompatibility antigen mismatches and cancer related antigens can
be expressed to the donor immune system. This effect is known as the graft-versusleukemia (GVL) effect22,26. By recognizing and eliminating residual leukemic cells that
have survived conditioning, the donor immune cells can significantly lower relapse rates
by clearance of latent disease post-conditioning. This is one of the main understood
therapeutic mechanisms of action of allogeneic HSCT. Conditioning can be effective at
removing residual cancerous cells, but these residual cancer cells can also be prime target
for alloreactive elimination by the donor immune system. It is therefore unsurprising that
the degree of GVHD is often inversely correlated with relapse rates; a patient who develops
severe GVHD will likely have sufficient alloreactivity to kill the residual cancer cells.
Considering the potentially detrimental character of GVHD compared to the beneficial
effects of GVL , separating GVHD from GVL is one of the main goals of research in this
field.

1.4

Graft-versus-host disease
Graft-versus-host disease (GVHD) is the single biggest limiting factor of the

widespread use of HSCT. While infections, veno-occlusive disease, and mucositis can also
cause patient morbidity and mortality, they are either not as common or not as severe
11

outside the context of GVHD. Therefore, prevention of GVHD is one of the main goals of
the transplant field, as deaths due to GVHD account for 20 percent or more of the mortality
after transplant27. Moreover, quality-of-life can be significantly affected in both acute and
chronic GVHD.
GVHD can potentially affect any organ system and occurs in roughly 50 percent of
patients post-transplant. Severity of GVHD can be mild to severe; gut GVHD is both
common and potentially deadly in an acute setting, while skin and lung chronic GVHD are,
respectively, the most common and most deadly forms of chronic GVHD.

1.4.1

Acute graft-versus-host disease
Acute GVHD is often induced by conditioning-related tissue damage, wherein

damaged tissue releases danger signals which activate host-derived APCs, which can cause
T-cell activation and proliferation These danger signals often include TNF-alpha, IL-1
beta, and lipopolysaccharide, with the latter occurring by release of endogenous bacteria
into systemic circulation. The signals themselves and the responding cells that they activate
contribute to a phenotype known as a “cytokine storm,” wherein massive levels of
inflammatory cytokines are released28. This cytokine storm can cause organ failure and
lead to patient mortality by itself or in combination with other factors. Historically, aGVHD
was classified as any GVHD that occurs less than 100 days post-transplant, but this
definition has largely been superseded by clinical presentation of disease and the
recognition of late acute GVHD29. Late aGVHD can manifest more than 100 days after
transplant but still display the characteristic signs and symptoms of aGVHD.
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As has been mentioned, host-derived dendritic cells (DCs) are key drivers in early
allogeneic T-cell responses. In addition, donor-derived DCs, once they are produced from
the marrow, can amplify alloreactivity from T-cells and associated inflammatory cytokine
production. . These responses often include massive cytokine production either directly
from T-cells or from cells activated by the T-cell response, especially type I cytokines such
as IL-1beta, TGF-beta, TNF-alpha, IL-2, and IFN-gamma30.
In the case of an MHC-mismatched transplant, direct mismatching can lead to
immunodominant T-cell clones and progressive aGVHD. However, high levels of HLA
mismatch are increasingly rare in the clinical setting, and alloreactive T-cells often
establish immunodominant clones that recognize minor histocompatibility antigens31.
Presence of these clones can be predictive of GVHD onset, and sometimes the course and
severity of the disease.
Acute GVHD is graded as Stage I-IV for each organ, with IV being the most severe.
Primary organs involved are skin, liver, and upper and lower GI tract. Skin is the most
common, and liver is least common. Upper GI disease presents in 24-60 percent of patients
but is likely underreported due to the difficulty of biopsy. Lower GI tract GVHD has the
highest risk of non-relapse mortality for patients after transplant. Biopsies of affected
organs are often taken to confirm an initial diagnosis of aGVHD and to rule out other
diagnoses29.
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1.4.2

Chronic graft-versus-host disease
Chronic GVHD is a late complication that occurs in about 50 percent of patients

that have undergone hematopoietic stem cell transplant. In contrast to acute GVHD, which
is characterized by acute inflammation, massive cytokine production, and barrier
dysfunction, chronic GVHD appears much more autoimmune in its mechanisms of
pathogenesis. It is complex and poorly understood but is known to involve crosstalk and
interactions between T-cells, B-cells, neutrophils, and tissue resident cells. One of the
primary characteristics of cGVHD is inappropriate collagen deposition induced by an
aberrant wound-healing mechanism23. Post-conditioning, tissue-resident cells attempt to
regulate the initial cytokine storm of acute GVHD through production of anti-inflammatory
cytokines and fibrogenetic factors to repair tissue damage23. This production of antiinflammatory mediators, while initially helpful in controlling alloreactive immune
responses, leads to inappropriate collagen deposition and fibrotic disease.
cGVHD can affect any organ system, with key symptoms often related to increased
collagen deposition. Histologically, these changes are often seen to be relatively acellular,
although this can change depending on the disease presentation. This fibrotic phenotype is
an irreversible, end stage disease, and while symptom management has improved, overall
incidence has not decreased. For instance, lung involvement of cGVHD has been
underestimated for decades32. Both restrictive and obstructive lung function changes are
found, and bronchiolitis obliterans syndrome (BOS) is now understood as a classical form
of cGVHD of the lung. It is one of the only pathognomonic symptoms of cGVHD and is
associated with particularly poor prognosis due to these irreversible structural changes in
the architecture of the lung.
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While aGVHD is a risk factor for later onset of cGVHD, the two can occur
independently. Therefore, it is possible for a patient to develop aGVHD, recover, and never
develop cGVHD. Alternately, a patient can develop de novo cGVHD without ever having
developed aGVHD. Late cGVHD can even develop years or decades post-transplant; a
patient who has previously shown no signs of GVHD can be subject to some initiating
insult leading to onset of the disease. Our understanding of what events begin this process
is severely limited and can severely limit a patient’s return to normal life and everyday
behaviors after transplant.
Ultimately, cGVHD is a disease whose treatment is hampered by an incomplete
picture of the events that initiate and maintain its progression. Certain patient populations
and characteristics, underlying diseases, aGVHD status, conditioning regimens, viral
seropositivity status, and many other factors contribute to whether a given patient develops
cGVHD and the type of disease that manifests28,33. Therefore, it is best to approach
treatment of cGVHD mechanistically; targeting of pathways involved will likely have a
better outcome than attempting to control each factor pre-transplant. This is an approach
that has thus far borne fruit. The finding that germinal center B-cells were involved in
cGVHD pathogenesis in multiple organ systems led to the preclinical use of ibrutinib, a
BTK inhibitor34.
Cytokines and chemokines are important in cGVHD. In a study of nearly 300
patients with cGVHD, the CXCR3 ligand CXCL10 was identified as the only consistent
serum biomarkers of the disease in both of the cohorts that were analyzed35. At the same
time, a combination of biomarkers including CXCL10 and BAFF seemed to have better
prognostic value than either alone, although this work is still ongoing and being replicated
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in multicenter studies. At the tissue level, dysregulated TGF-beta signaling seems to be
very important in establishment of pathogenic fibrosis36. TLR pathway activation can drive
production of IFN-gamma, IL-6, and IL-1 beta, which together can promote Th17
differentiation and pathogenic IL-17 production37–39. IL-33 production by damaged tissue
can also further activate fibroblasts and immune cells, mast cells included40. Together,
these factors drive a positive feedback loop of chronic inflammation alongside aberrant
wound-healing responses, which can drive fibrotic disease.
Targeting specific pathways in cGVHD also has benefit for minimalization of the
GVH response. Our work with mast cells takes this approach; we demonstrate that tissueresident mast cells that are critical in initiation of cGVHD41. Specific inhibition of these
cells may therefore allow for GVL without GVHD. Overall, control and prevention of
cGVHD will not be possible until further research is completed that allows a deeper
knowledge of pathways involved, which will hopefully allow for immune and cGVHD
suppression while retaining the potentially curative GVL effect.

1.4.2.1 Dermal involvement in chronic graft-versus-host
disease
In chronic GVHD, the most frequently involved organ is the skin, with symptoms
often presenting as sclerosis alongside increased collagen deposition42,43. Scleroderma-like
cGVHD observed in transplant survivors can result in skin thickening and stiffness at
localized sites or can manifest over extended areas of the body which can lead to full loss
of mobility and entire body encasement. Other cutaneous manifestations of cGVHD
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include lichen planus-like disease, morphea-like features, depigmentation, erythema, and
ulceration4,44. In addition to the social stigma of widespread skin disease, these
manifestations can have a significant negative impact on patient quality of life.
Histologically, sclerotic dermal cGVHD presents as a thickening of the dermis due
to massively increased collagen deposition. This collagen layer is relatively acellular,
though fibroblasts are still present alongside scattered infiltrating cells44. Skin
manifestations of cGVHD occur in 70% of patients, with sclerotic disease presenting in
15-40% of cGVHD patients42,45,46.

1.4.3

Murine models
In humans GVHD can manifest in many different organ systems and display an

incredibly wide range of clinical symptomology. For decades, researchers have used
murine models of bone marrow transplant as a surrogate for human disease. These models
are performed by transplanting bone marrow and/or splenocytes harvested from a donor
mouse into a recipient mouse that has undergone conditioning. This conditioning, as in
patients undergoing HSCT, is most often based on chemotherapy or total body
irradiation47.
Used as a negative controls that should not show the disease phenotype, syngeneic
transplants are readily achievable in murine models by using genetically identical mice of
the same strain. Allogeneic transplants are often used to model graft-versus-host disease,
the severity, penetrance, and organ-specific manifestations of which depend on the degree
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of MHC-matching between the donor and recipient, the T cell dose, and the conditioning
intensity. Murine allogeneic transplants, while they do not individually capture the entire
clinical spectrum seen in human disease, allow for a more focused analysis of specific
aspects of GVHD. As with GVHD itself, these models are broadly subtyped into those that
induce acute or chronic disease, and GVHD phenotype is to some extent strain dependent.
Generally, a full MHC-mismatched transplant (such as the widely used BALB/C
[H2b]  C57BL/6 [H2d] model) displays characteristics of acute GVHD, with severe
wasting, gut dysfunction, massive inflammation, and death occurring in most animals
within 14 days48. Most often, a lethal dose of total body irradiation is used to condition the
recipient mice, the radiation source, fractionation, and duration of which can change the
characteristics and severity of the cytokine storm phase of aGVHD. To better correlate
murine models with a clinical transplant setting where MHC mismatching is rare, mouse
models of aGVHD have been developed that rely entirely on minor histocompatibility
mismatches. These models, including the DBA/2  B10.D2 (H2d  H2d)49 and C3H.SW
 C57BL/6 (H2b  H2b)50, develop lethal aGVHD although the phenotype of the disease
can differ between models.
Mouse models of cGVHD attempt to recapitulate the smoldering inflammation,
thymic dysfunction leading to dysfunctional Treg cells, and pathogenic fibrosis often seen
in patients51. Sclerodermatous disease is most common in the skin, and two miMHCmismatched mouse models of transplant (TBI conditioning followed by B10.D2 
BALB/C52 or LP/J  C57BL/653) display extensive scleroderma and limited mortality,
with fibrosis and dermal thickening evident from day 30 onward. Autoantibody deposition
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leading to lupus-like symptoms are also characteristic of cGVHD and can be modeled with
the DBA2  B6D2F1 model, which results in splenomegaly due to B-cell expansion.
Depending on the dose of conditioning, cytokine milieu, donor marrow, or donor
splenocytes, some models using the same level of MHC mismatch can be shifted to display
symptoms of aGVHD or cGVHD. For instance, the DBA2  B6D2F1 model of
autoantibody-mediated cGVHD can be skewed towards aGVHD through the addition of
IL-12, a classical Th1 cytokine54. Further, the LP/J C57BL/6 model, when used with
excess splenocytes or a higher radiation dose, develops fulminant and lethal aGVHD34.
Measurement of murine GVHD severity is assessed by scoring systems that
monitor the overall health and liveliness of the animal. Cooke et al. published on a system
that is used in our lab and has been extensively adopted by the field55. Mice are scored for
GVHD by assessment of five clinical parameters: weight loss, posture (hunching), activity,
fur texture, and skin integrity. Individual mice receive a score of 0 to 2 for each criterion
(maximum score of 10) that is used as an index of severity and progression of disease.
Scoring systems such as these allow for animal experiments to be performed humanely in
addition to giving each lab a measurement that can be used to track transplant outcome.

1.5

Immune involvement in graft-versus-host disease
Immune cells are the main driver in the symptoms of GVHD. Although there is still

much debate as to the relative contributions of each cell type, T-cells are considered to be
the canonical effector cell in GVHD, with CD4 and CD8 T-cells each involved in the onset
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of the disease. In addition, macrophages, B-cells, neutrophils, and as the subject of this
dissertation, mast cells, have all been shown to play a role in the onset or maintenance of
GVHD.

1.5.1

Adaptive immunity
GVHD has traditionally been defined as a disease driven by alloreactive donor-

derived CD4 and CD8 T-cells responding to non-self antigens presented by host-derived
antigen-presenting cells (APCs) and target tissues30. While this is certainly true in aGVHD,
in recent years, studies have shown a heavy level of B-cell involvement in cGVHD as well,
particularly germinal center B-cells through their IL-21 mediated interactions with Tfollicular helper cells24. While relative contributions are difficult to deconvolute, it is
abundantly clear that adaptive immunity is a major driver of pathogenesis in both acute
and chronic GVHD.
The cytokine storm phenotype that can often occur in the early phases of aGVHD
potentiates host-derived APCs to activate donor-derived T-cells. This occurs through
presentation of self-antigens, which induces alloreactive donor T-cell activation and
proliferation, followed by their trafficking to the tissues and causing many of the
pathologies associated with GVHD.
Th1, Th2, and Th17 cells have all been shown to play a role in pathogenesis of
GVHD. In aGVHD, proinflammatory Th1 cells are the primary T-cells involved, while in
cGVHD, Th2 and Th17 cells have both been shown to play a role. This takes place
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especially through production of IL-17A, IL-4, and IL-13, which can promote fibrosis and
production of alloreactive antibodies. In aGVHD, a unique subset (non Th1, Th2, Th17) of
granzyme A-producing Th cells has also been shown to further disease progression through
a STAT3-dependent mechanism56.
Tfh cells seem to be more directly involved in fibrotic manifestations of GVHD.
ICOS+, IL-21-producing Tfh cells are known to contribute to skin fibrosis in other models
of scleroderma57, and this appears to be the case in cGVHD as well. Flynn et al. showed
that Tfh cells produce IL-21 in cGVHD, which promotes germinal center formation and
autoantibody production from GC B-cells, thereby increasing disease burden. Inhibition of
this process through IL-21 blockade reversed this finding24.
In contrast to other T-cells Tregs are a cell type involved in tissue homeostasis and
downregulation of inflammation. Almost universally in sites of GVHD-mediated tissue
damage, there is a significant increase in the T-effector:Treg ratio. Homeostatic control of
GVHD can be maintained in settings that promote Treg survival and proliferation or after
exogenous addition of Tregs. Given the differences in the tissue environment between
acute and chronic GVHD, it is perhaps surprising that Tregs seem to be critical for
reduction of disease in both settings27.
B-cells are also implicated in GVHD pathogenesis. For acute GVHD, the evidence
of B-cell involvement is not as strong as for chronic GVHD; recipient B-cells are thought
to be eventually eliminated after HSCT and donor B cells are not as significant of a
proportion of the graft as T-cells. In combination with the evidence that GC B-cells may
be drivers of pathogenesis in cGVHD, it seems that these are donor-derived B-cells that
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may not be numerous or mature enough to play a major role in early aGVHD. As a proof
of concept, a drug targeting BTK, is the only FDA-approved drug for chronic GVHD and
has been shown to reduce GVHD and enhance GVL in murine models34. In cGVHD, BAFF
signaling is found to be hugely important for B-cell pathogenesis, with long-term
overexpression of BAFF levels alongside antigenic signaling driving B-cell proliferation
and antibody production58.
Of course, as GVHD is such a heterogenous disease, different aspects of adaptive
immunity can be at play in local sites within the same patient. This makes biomarker studies
particularly difficult. For instance, liver and skin fibrosis can both occur in cGVHD, but
seem to do so by different mechanisms, with Tfh cells being more important for
scleroderma, and Th17 cells being critical for development of liver fibrosis59.
1.5.2

Innate immunity
While the adaptive immune system is critically important in GVHD, there is an

increasing body of research showing that innate immunity also plays a large role on its own
as well as in initiating and amplifying adaptive immune responses. Induction and
maintenance of innate immune responses through cytokines including canonical proinflammatory factors such as IFN-γ, TNF-α, IL-1, and IL-6, as well as more mercurial
cytokines including TGF-β, IL-10, and IL-17, have all been demonstrated in recent years.
In addition to establishing this proinflammatory environment through cytokine production,
innate APCs such as dendritic cells or macrophages are critical to activating donor-derived
T-cells.
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The innate response is thought to be initiated through loss of intrinsic barriers or
transient tissue damage, leading to bacterial infiltration and the release of pathogenassociated-molecular-patterns

(PAMPs)

and

damage-associate-molecular-patterns

(DAMPs)60. Innate cells generally express very high level of DAMP and PAMP receptors
and are exquisitely sensitive to stimulation by these classes of molecules. Tissue damage
and loss of physical barriers leads to further stimulation and cytokine production by tissueresident cells, which then exacerbate the initial insult through the establishment of a
feedback loop of chronic inflammation characteristic of GVHD.
One of the critical steps in acute GVHD is presentation of self-antigen by recipient
APCs to alloreactive donor T-cells. For example, in the gut, conditioning causes a
breakdown in the epithelial barrier, leading to IL-33 release from damaged cells, LPS and
other PAMPs from gut commensal bacteria that cross the damaged barrier, and DAMPs
such as extracellular DNA or ATP, uric acid, and HMGB161. These bind to ST2, TLR4, or
other receptors on the cell surface. The receptor repertoire expressed by an individual cell
can drive its response in different directions. Exemplary of this is ATP, which binds to
P2X7 on mast cells and induces degranulation, but binds to P2Y2 on macrophages and
stimulates IL-1b production62. For dendritic cells, this multitude of signals is often
integrated by coming together through activation of a central transcription factor such as
NF-kB or AP1. This integrated signal helps to drive the DC to maturation and enhances its
antigen presentation and T-cell stimulatory capacity, allowing for the detrimental
alloreactive responses seen in gut GVHD60.
Neutrophils and macrophages are often among the first cells to respond to an injury
or insult. These cells are activated by the tissue damage and commensal infiltration,
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producing reactive oxygen species (ROS) in an attempt to sterilize the area. This ROS
production can lead to tissue damage and enhancement of GVHD; patients with defective
ROS production, as in chronic granulomatous disease, have significantly reduced rates of
GVHD after transplant. In both acute and chronic GVHD, tissue damage mediated by these
granulocytes (among others such as eosinophils, whose absence in the tissues is a
biomarker of improved clinical outcome63) is very common48.
The concept of mast cells as initiators of fibrosis has come to prominence in recent
years, but until our work, it had not been studied in the context of chronic GVHD.
Preliminary research on this topic was performed several decades ago although it has not
since been thoroughly investigated, likely because of the lack of effective models of mast
cell deficiency and the need for better murine models of cGVHD64,65. The development of
mast cell-deficient mice and refinement of the murine models of allo-HSCT has now
allowed for a more thorough investigation into the role of mast cells in cGVHD
pathophysiology. Previous work by Leveson-Gower et al. has shown that the presence of
mast cells is beneficial in the context of acute GVHD through mast cell production of antiinflammatory factors, such as IL-1066. However, that study was performed in a C57BL/6
 BALB/c model of acute GVHD, where defining characteristics of the disease include
acute inflammation and early alloreactive damage to the tissues, along with rapid disease
onset, progression and mortality from acute GVHD. In contrast, chronic GVHD is often
defined by inappropriate and prolonged inflammation alongside anti-inflammatory “wound
healing” responses and fibrosis. Therefore, we believe that the mast cell, while beneficial
in the inflammatory phase of aGVHD, ultimately becomes detrimental in cGVHD through
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its ongoing anti-inflammatory activities resulting in collagen deposition and pathogenic
fibrosis.
Chemokine production by innate immune cells is a key mediator of increased tissue
recruitment of other innate cells as well as alloreactive adaptive cells. The T-cell
chemoattractants CCL5, CXCL9, CXCL10, and CXCL11 are considered to be some of the
most consistent disease biomarkers in both acute and chronic GVHD35,67. Furthermore,
without CCR1/CCL5 signaling, donor T-cells have been shown to have greatly decreased
proliferation and IFN-gamma secretion68. This indicates that these molecules are not only
important for inducing migration in T-cells, but that they help prime functional activity as
well.

1.6

Therapeutic options in graft-versus-host disease
Treatment options in GVHD are initially focused on preventing and treating the

acute phase of the disease. Methotrexate and cyclosporine/tacrolimus are often used for
GVHD prophylaxis. More recently, and particularly in the setting of haploidentical
transplants, post-transplant cyclophosphamide is used to reduce early GVHD and to
suppress and cause cellular dysfunction in alloreactive clones15. Patients who develop
grades III-IV acute GVHD have a very poor survival, with one study reporting an 8 percent
5-year survival rate69. Therefore, minimization of disease burden is crucial, and
corticosteroids or broad-spectrum immunosuppressants are first-line therapies. Antithymocyte globulin is also used to suppress T-cell responses, especially in patients
refractory to corticosteroids.
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A major challenge with immunosuppression is the loss of the GVL effect, since
immunosuppressants reduce donor immunosurveillance. Patients also suffer from higher
rates of stem cell engraftment failure when dosed with increasing doses of
immunosuppressant. Therefore, it is necessary to taper a patient’s dose of
immunosuppressants as soon as clinically possible7. cGVHD is also treated primarily using
immunosuppressive and anti-inflammatory approaches, yet responses are not satisfactory
and long-term treatment is associated with poor tolerability and risk of severe and
potentially lethal infections.
cGVHD has recently seen several treatment options become available, especially
small molecule tyrosine kinase or Jak-Stat pathway inhibitors. Ibrutinib (trade name:
Imbruvica) was shown to be effective at inhibiting GVHD progression in murine models
of sclerodermatic and pulmonary GVHD34, after which it moved on to human trials and
received FDA approval in 201770,71. Ruxolitinib (trade name: Jakafi) is a Jak1 and Jak2
inhibitor, proteins which serve as signal transduction molecules downstream of some
cytokine receptors, such as the Type I IFN receptor. Ruxolitinib was recently approved for
steroid-refractory aGVHD and is currently in phase III clinical trials for steroid-refractory
chronic GVHD72,73.
Overall, there is a clear need for a better clinical armamentarium for both acute and
chronic GVHD. Immunosuppression does not always sufficiently repress aGVHD and
does not reduce incidence or severity of cGVHD, in addition to opening the door to
potentially lethal infections or relapse of primary disease. Next-generation drugs such as
ibrutinib and ruxolitinib show promise, but further work is needed to verify the patient
populations in which they can be of the most use.
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1.7

Mast cells
Mast cells are myeloid granulocytes traditionally defined by their role in allergy

through release of proinflammatory mediators such as histamine and heparin. Mast cells
differentiate in the bone marrow from CD34+ progenitor cells, then travel to and mature in
tissue. These long-lived cells then remain in the tissue, where they are involved in
immunosurveillance, wound healing, and defense against helminth parasites74.
After staining with toluidine blue, mast cells are visually striking and easy to
identify, being filled with azurophilic granules containing a wide variety of mediators
including histamine, heparin, prostaglandins, and proteases such as tryptase and chymase.
These granules are released upon binding of IgE and a cross-linking antigen to the
immunoglobulin E (IgE)/FcεRIα complex. This initiates a signaling cascade leading to
release of preformed granules as well as inducing de novo synthesis and concomitant
release of a wide array of extracellular mediators including cytokines, chemokines, and
growth factors. Without this IgE/antigen crosslinking, mast cells will have a drastically
reduced response to other stimuli75.
However, mast cells can also be activated by other methods. Of particular interest
in GVHD may be IL-33-based mast cell activation. IL-33 is produced by damaged tissues
and binds to ST2 on the surface of the mast cell, inducing degranulation and synthesis of
an array of cytokines and chemokines largely distinct from those produced during IgEmediated degranulation. The particular products secreted by mast cells vary based on
location and surroundings, with the cytokine profile present in the microenvironment
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largely determining which proteins are expressed upon degranulation. For instance, in an
inflammatory environment, mast cells have been shown to release regulatory factors and
to enhance Treg responses in order to equilibrate their environment75,76.
Interestingly, the skin and lungs are some of the primary tissue niches for mast
cells, as well as some of the primary target organs for cGVHD, leading one to question
whether mast cells may play a role in disease progression. Previous studies have
demonstrated that mast cells degranulate early in cGVHD pathogenesis, the act of which
makes histologic identification difficult and has led to the phenomenon of “phantom” mast
cells in skin samples. Yet these mast cells still exist in situ, and as the disease progresses,
they recover granulocyte function and once again begin acting as effector mast cells. This
initial work was done by Henry Claman and others in the 1980’s and hinted at an initiating
role for mast cells in the onset of cGVHD64,65,77,78.

1.7.1

Role in immunity
Mast cells are primarily known for their granules. It is the first notable feature when

viewing the cell and was the source of its name, first defined by Paul Ehrlich in his doctoral
thesis. Believing the granules to be a source of nutrients for surrounding cells, he christened
them Mastzellen, meaning “fattening cells” in his native German. Today, we know those
granules to contain a wide variety of active agents which allow mast cells to fulfill their
myriad of roles79.

28

Canonically, the mast cell is primarily involved in helminth infection. Mast cell
production of IL-4, IL-5, and IL-13 help to polarize the immune environment towards Type
II immunity which is beneficial for anti-helminth immune responses80. Mast cell proteases
can help to digest and destroy pathogens too large for normal cellular immunity to deal
with. Additionally, histamine and other mediators produced by mast cells cause contraction
of smooth muscle, which can assist in physical expulsion of the parasite.
Mast cells have also been shown to be crucial for minimizing damage from
envenomation. Most venoms are peptides, and mast cells, being preloaded with a wide
variety of proteases in their granules, are uniquely equipped to neutralize them. Studies
have shown that mast cell chymase, among other proteases, can neutralize venom from
reptiles such as Gila monsters and snakes, as well as venoms involved in insect bites and
stings80–82.
Due to their tropism to skin and mucosal sites, mast cells are often among the first
cells to respond to breaches in physical barriers. Mast cells express a wide variety of
receptors, including TLRs, ST2, and various chemokine and cytokine receptors that can
recognize tissue damage or pathogens entering the local area. Mast cell responses to
stimulation through these receptors can range from aggressive degranulation to low-level
but sustained cytokine production75. Chemokine production from mast cells is critically
important for this process; mast cells are capable of recruiting a huge variety of immune
cells including but not limited to T-cells, B-cells, neutrophils, eosinophils, and
macrophages.
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In addition to their role as sentinel cells, mast cells are also important for wound
healing and repairing tissue damage. This can take place through promotion of
angiogenesis by VEGF, bFGF, and TGF-beta79. Histamine also increases vascular
permeability and allows for increased recruitment of cells that contribute to sterilization of
the injury site. Additionally, mast cells are involved in wound healing, both directly and
indirectly. Mast cell proteases chew back the damaged tissue, while mast cell interactions
with fibroblasts induce proliferation, myofibroblast differentiation, and collagen
deposition, which promote wound closure and tissue remodeling83.

1.7.2

Pathologies
Despite the beneficial aspects of mast cells in immunity, they are often

characterized more by their detrimental effects. Nearly everyone has experience with mast
cells in the context of allergy; any time someone takes an antihistamine, they are aiming to
inhibit mast cell responses. However, mast cells can also be detrimental in other contexts,
especially where there are other aspects of immune dysregulation.
For decades, mast cells have primarily been thought of for their role in
allergic inflammation. Mast cell activation is shown to be chronic and prolonged in
asthmatic patients, and those with chronic itch and urticaria also have pathologic mast cell
responses84. Mast cell involvement in allergic disease can often be detected by
measurement of serum tryptase levels. However, this comes with a caveat; tissue-localized
mast cells have to produce massive amounts of tryptase for it to be present in detectable
levels in the serum, therefore this test can be subject to false-negative results.
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Asthma is one of the most common chronic diseases in the world, and mast cells
are critical in both the initial anaphylactic response as well as the later stages of airway
remodeling77,85,86. Mast cell histamine and TNF-alpha induces smooth muscle contraction
and swelling, which can lead to airway obstruction. IL-4 and IL-13 produced by mast cells
induce B-cell class switching to IgE which can lead to anti-allergen IgE responses,
sensitizing a patient to further exposure. Additionally, in the context of chronic
inflammation, B-cells can produce IgE autoantibodies, kicking off a positive feedback
loops of IgE/mast cell driven inflammation. Additionally, mast cell growth factor and
tryptase production can lead to airway remodeling by restrictive thickening of the basement
membrane and hyper-production of mucus86.
Mast cells are also implicated in diseases outside of allergy. For instance, defective
wound healing responses and pathological fibrosis have been shown to be mast cell
dependent in many diseases or model systems77,85,87–89. These responses make sense when
considered alongside the physiological roles of mast cells; wound healing and angiogenic
responses are known to function poorly when taking place during chronic inflammation
such as that seen in cGVHD.

1.8

Overall Hypothesis
cGVHD is a debilitating disease and much of its symptomology is due to

pathogenic fibrosis. This proposal aims to determine the mechanism by which this
pathogenic fibrosis is propagated, the understanding of which is currently very limited. The
identification of mast cells as potential initiators of fibrosis in cGVHD would tie together
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many disparate threads in the study of GVHD, as the transition from acute to chronic
GVHD, or even the rise of de novo chronic GVHD, is complex and incompletely
understood. We hypothesize that mast cells in the tissue contribute to the pathogenesis of
dermal manifestations of chronic graft-versus-host disease through chemokine production
and establishment of a profibrotic environment. We further hypothesize that mast cells
propagating cGVHD of the skin are of recipient origin due their mature developmental
stage and low susceptibility to radiation induced death.
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CHAPTER 2. MATERIALS AND METHODS
2.1

Animals
All animal work was approved by the University of Kentucky Institutional Animal

Care and Use Committee and the Department of Laboratory Animal Resources, protocol
number 2016-2488. BALB/cJ, LP/J, C57BL/6J, and B6.Cg-KitW-sh/HNihrJaeBsmGlliJ
mice were all purchased from commercially available sources (Stock numbers 000651
(RRID IMSR_JAX:000651), 000676 (RRID IMSR_JAX:000676), 000664 (RRID
IMSR_JAX:000664), and 012861 (RRID MMRRC_012861-UCD), respectively. Jackson
Laboratories, Bar Harbor, ME, USA). To minimize gender effects on this mechanistic
study, all mice were female and were used at 8-10 weeks of age.

2.2

Hematopoietic transplantation model
C57BL/6J, B6.Cg-KitW-sh/HNihrJaeBsmGlliJ, or LP/J donor mice were sacrificed

by CO2 inhalation, then bone marrow cells and splenocytes were isolated and counted.
C57BL/6J and B6.Cg-KitW-sh/HNihrJaeBsmGlliJ recipients were exposed to a single dose
of 850cGy of ionizing radiation from a Cesium source, then injected intravenously with
2.0x106 LP/J splenocytes and 5.0x106 LP/J bone marrow cells. Alternatively, mice were
conditioned with busulfan/cyclophosphamide as previously described, adapted to our
chronic GVHD model90. Briefly, mice were injected intraperitoneally for 5 days with
busulfan from day -7 to -3 at 15mg/kg. Cyclophosphamide dosing at 100mg/kg took place
for two days alongside busulfan on days -4 and -3. Mice were then given two days to rest
without dosing prior to injection of donor cells at the same dose as in the TBI model. In
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the syngeneic group, C57BL/6J mice received the same dose of splenocytes and bone
marrow cells from a C57BL/6J mouse. After week 7, blood was collected into heparinized
tubes (365965, BD Biosciences, San Jose, CA). Heparin tubes were centrifuged at 1500xG
for 10 minutes, then plasma was harvested and stored at -80C. Skin, lung, liver, small
intestine, colon, kidneys, ear, and tracheal tissue were harvested, trisected, and stored either
in formalin for histologic analysis, in RNALater (AM7021 , Millipore-Sigma, St. Louis,
MO) for RNA stabilization, or snap-frozen over dry ice for protein analysis, then stored at
-80°C. Splenocytes were harvested for flow cytometric analysis.

2.3

GVHD scoring
Recipient mice were monitored daily for survival, and clinical GVHD was assessed

weekly by a lab member not directly involved in the planning of the study. Mice were
scored for GVHD by assessment of five clinical parameters: weight loss, posture
(hunching), activity, fur texture, and skin integrity. Individual mice from coded cages
received a score of 0 to 2 for each criterion (maximum score of 10) that was used as an
index of severity and progression of disease55.

2.4

Mast cell culture
Bone marrow was extracted from femurs and tibias isolated from BALB/cJ or

C57BL/6J mice and cultured in DMEM media (12-604F, Lonza, Basel, Switzerland) with
10% heat-inactivated fetal bovine serum (35-011-CV, Corning Inc., Corning, NY) and 1%
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penicillin/streptomycin (120-095-721EA, Quality Biological, Gaithersburg, MD) at 37C,
5% CO2, in a humidified incubator. After 24 hours, the suspension cells were removed and
cultured in a new flask along with 10ng/ml recombinant murine IL-3 (213-13, Peprotech,
Rocky Hill, NJ). Cells were passaged twice per week, each time leaving behind any
adherent cells. After 4-6 weeks, cell phenotype was confirmed by visual morphology and
flow cytometry.

2.5

Mast cell irradiation/chemotherapy viability assay
Viable mast cells were counted by hemacytometer via trypan blue exclusion and

plated at 1e6/ml, then exposed to 8.5 or 20Gy single-dose radiation from a cesium source
or chemotherapeutic agents. Busulfan and cyclophosphamide were purchased from
Cayman Chemicals (14843 and 13849, Ann Arbor, MI) and resuspended in DMSO.
Drugging time and conditions were chosen based on clinical usage91. Cells were drugged
with 800ng/ml busulfan and/or 30ug/ml cyclophosphamide, which corresponded to steadystate serum levels of the drug during clinical utilization91. Cells were approximately 98%
viable prior to irradiation. Every 24 hours, cells were counted and assessed for viability by
trypan blue exclusion out to 96 hours post-irradiation or 72 hours post-drugging.

2.6

Mast cell stimulation and inhibition assays
Mast cells were incubated overnight with 100ng/ml murine monoclonal anti-DNP

IgE, clone SPE-7 (D8406, RRID:AB_259249, Millipore-Sigma, St. Louis, MO) at 37C.
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The next day, cells were centrifuged and washed twice with fresh media to remove
unbound IgE and cells were replated in fresh media with 10ng/ml IL-3. Stimulation was
added to the relevant wells in the form of 10ng/ml IL-33 and/or 100ng/ml DNP-BSA for
24 hours at 37C, then cells were centrifuged and supernatant was collected. For the drug
inhibition assays, ibrutinib, ruxolitinib, imatinib, and fingolimod were purchased from
Cayman Chemical (936563-96-1, 941678-49-5, 220127-57-1, 162359-55-9, Ann Arbor,
MI) and reconstituted per the manufacturer’s instructions. Drug stocks were diluted in
media and incubated with mast cells after the overnight IgE incubation step. Cells were
treated for one hour at 37C, then washed out with fresh media twice. Cells were then
stimulated as per above.

2.7

Degranulation by CD107a expression
Cells were incubated at 1e6/ml with IgE overnight then washed and plated in new

media, as above. 0.66ul/ml Golgistop (554724, BD Biosciences, San Jose, CA) was added
along with AF594-CD107a antibody, clone 1D4B, (121624, RRID:AB_2616690,
Biolegend, San Diego, CA), then cells were stimulated with 100ng/ml DNP-BSA and/or
50ng/ml SCF (250-03, Peprotech) for 4 hours at 37C. Cells were then collected, washed,
and fixed/permeabilized with Fix/Perm reagent (554714, BD Biosciences). Cells were then
stained with BV421-CD117 (clone 2B8, 105827, RRID:AB_10898120) and PE-FCeR1a
(clone MAR-1, 134307, RRID:AB_1626104) (Biolegend) in perm/wash buffer for 20
minutes at 4C, washed, and analyzed by flow cytometry for CD117/FCeR1a +/+ CD107
+/- expression.
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2.8

Histology
Organs were collected from mice and suspended in 4% formalin for 48 hours, then

70% ethanol for 7 days. After this, samples were cut into slices, processed, and embedded
in paraffin blocks. All sections shown were sectioned at 5 micron thickness. Masson’s
trichrome staining was performed according to manufacturer protocol (26367-Series,
Electron Microscopy Sciences, Hatfield, PA). H+E stains were performed by the
University of Kentucky Surgical Pathology core and assessed by a blinded, board-certified
pathologist according to a previously published organ-specific GVHD scoring system50,55.
Skin slides were stained with Toluidine Blue O (364-12, Millipore Sigma) and assessed as
toluidine blue-positive cells per high-power field. Counts were verified by a separate,
blinded researcher. Texas Red-conjugated avidin was purchased from Rockland
Immunochemicals (A003-09, Limerick, PA) and resuspended at 2mg/ml in deionized
water. This was diluted 1:500 and sections were stained for 1 hour, washed 3 times in PBS,
dehydrated to xylene, and mounted with Fluoroshield Mounting Medium with DAPI
(ab104139, Abcam, Boston, MA).

2.9

Immunohistochemistry
Slides were baked at 80C for 15 minutes, then rehydrated through xylene, 100%,

95%, and 70% ethanol into H2O. Antigen retrieval was performed in citrate Target
Retrieval Solution (S169984-2, Agilent, Santa Clara, CA), pH 6.0, in a pressure cooker.
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Slides were blocked for 30 minutes in PowerBlock (HK083-50K, Biogenex, Fremont, CA),
then incubated with primary antibody at a 1:200 dilution in PowerBlock. Antibodies used
were rabbit anti-mouse CD3e, clone D4V8L (99940, RRID:AB_2755035, Cell Signaling
Technologies, Danvers, MA), and mouse anti-human tryptase, clone AA1 (ab2378,
RRID:AB_303023, Abcam, Boston, MA). Slides were washed in PBS + 0.1% Tween 20
(PBS-T) and then incubated with secondary antibody. For CD3 staining, a drop of Dako
Envision+ HRP Anti-Rabbit Polymer (K4003, RRID:AB_2630375, Agilent) was added to
slides for one hour, then washed with PBS-T. For tryptase staining, Goat Anti-Mouse
Immunoglobulin/HRP (P0260, RRID:AB_2636929, Agilent) was used at a 1:1 dilution for
10 minutes and then washed with PBS-T. After washing, DAB chromogen (ab64238,
Abcam) was prepared according to manufacturer’s instructions and added to slides while
observing the staining under a microscope for 30 seconds (tryptase staining) or 2 minutes
(CD3 staining). The reaction was quenched in diH2O, then dehydrated to xylene. Slides
were mounted using Richard-Allan Scientific mounting medium (4112APG, Thermo
Fisher Scientific, Waltham, MA).

2.10 Microscopy and analysis
Histology slides were imaged by Aperio Scanscope XT digital slide scanner or by
a color camera system attached to a Nikon Eclipse 80i microscope. All scale bars are
100um. Trichrome and CD3 IHC slides were digitally scanned by an Aperio ScanScope
XT system. Dermal thickness was measured with the ruler tool across 10-20 areas of tissue.
Aperio methodology and results were checked and verified by a blinded pathologist. CD3
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and tryptase positivity was measured across the whole tissue by the Aperio Positive Pixel
Count V9 algorithm. Counts were also verified by ImageJ IHC profiler analysis by a
blinded, independent researcher. Fluorescence images were acquired on a Nikon Eclipse
TE2000-U microscope equipped with a DS-Qi1Mc camera.

2.11 Flow cytometry
Splenocytes were phenotyped using two different antibody panels. The first panel
consisted of lymphocyte and T-cell stains and allowed for identification of CD45, CD3,
CD4, CD8, and FoxP3 subsets. The second panel identified B-cells, neutrophils,
macrophages, and dendritic cells using stains for CD19, CD11c, CD11b, F4/80, and Ly6G.
Splenic tissue was forced through a 70 micron filter to create a single cell suspension and
cells were washed with PBS containing 4% FBS and incubated with FcR-block anti-mouse
CD16/CD32 (14-0161-82, RRID:AB_467133, Clone 93, eBioscience, San Diego, CA).
Cells then were incubated in a pre-optimized concentration of antibodies in a total volume
of 100μL. For intracellular staining for FoxP3, fixation and permeabilization were done as
per protocol using the fixation/permeabilization concentrate and diluent (00-5123-43,
eBioscience). The following antibody clones were used for splenocyte characterization:
FITC-CD3 (REA641, 130-119-798, RRID:AB_2751851), APC-CD4 (GK1.5, 130091-611,

RRID:AB_871692),

APC-Vio770-CD45

(30F11,

130-118-687,

RRID:AB_2733121), APC-CD11c (N418, 130-091-844, RRID:AB_244272), PE-CD19
(6D5,

130-092-041,

RRID:AB_871638),

FITC-F4/80

(REA126,

RRID:AB_2651700) (Miltenyi Biotec, Bergisch Gladbach, Germany)
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130-102-988,

PerCP-Cy5.5-CD11b (M1/70, 101228, RRID:AB_893232), PerCP-Cy5.5-CD8
(53-6.7, 100733, RRID:AB_2075239) (Biolegend, San Jose, CA)
PE-Cy7-Ly6G (RB6-8C5, 25-5931-81, RRID:AB_469662), APC-eFluor780MHCII (M5/114.15.2, 47-5321-82, RRID:AB_1548783), PE-FoxP3 (FJK-16s, 12-577380, RRID:AB_465935) (eBioscience)
Mast cells were phenotyped using the following antibody clones:
BV421-CD117 (clone 2B8, 105827, RRID:AB_10898120), PE-FCeR1a (clone
MAR-1, 134307, RRID:AB_1626104) (Biolegend)
All cells were analyzed on a BD LSR II cytometer (BD Biosciences) using singlestained OneComp eBeads (01-1111-41, Thermo Fisher Scientific, Waltham, MA) to
determine compensation values. All gates were set using fluorescence-minus-one (FMO)
controls. Flow cytometry data were analyzed using FlowJo V10 software (FlowJo Inc.,
Ashland, OR).

2.12 RNA isolation and NanoString analysis
Tissue was frozen in RNALater as described in “Transplant” methods. The tissue
was thawed, then suspended in 1ml of Ribozol RNA isolation solution (VWR, Radnor,
PA), and homogenized using a Tissuemiser homogenizer (Thermo Fisher, Waltham, MA).
RNA was isolated from the homogenate per the Ribozol manufacturer’s instructions. RNA
was quantitated using the Qubit RNA BR assay kit in the Qubit Fluorometer (Thermo
Fisher). 100ng of RNA was loaded into the cartridge of the NanoString Myeloid Innate
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Immunity panel and run on the nCounter Flex system at the University of Kentucky
Clinical Genomics core per the manufacturer’s instructions (NanoString Technologies,
Seattle, WA). Data normalization and analysis was performed in the nSolver software.

2.13 Real-time quantitative PCR
For cDNA synthesis and qPCR, RNA was quantified using a Nanodrop instrument
(Thermo Fisher), and 100ng was loaded into the iScript cDNA Synthesis Kit (1708891,
Bio-Rad, Hercules, CA). For IL21 gene analysis, a predesigned primer probe mix was
purchased from Integrated DNA Technologies (Assay ID: Mm.PT.58.7853071, Integrated
DNA Technologies, San Jose, CA) and normalized using ACTB as a housekeeping gene
(Assay ID: Mm.PT.39a.22214843.g). cDNA was assayed using the Luna Universal Probe
qPCR master-mix, (M3004X, New England Biolabs, Ipswich, MA) on an Applied
Biosystems StepOne Real-Time PCR System (Applied Biosystems, Foster City, CA).
Relative quantitation was performed using the delta-delta CT method, described
previously92.

2.14 Tissue lysate preparation
Tissue was snap-frozen on dry ice as described in the “Transplant” methods section.
The tissue was thawed, then suspended in 500ml 1x RIPA buffer (89900, Thermo Fisher,
Waltham, MA) with protease inhibitors added (cOmplete Protease Inhibitor Cocktail,
4693159001, Roche, Basel, Switzerland). Tissue was homogenized using a Tissuemiser
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homogenizer (Thermo Fisher). Homogenate was vortexed for 30 seconds, then put on ice
for 10 minutes. This procedure was repeated 3 times, then homogenates were spun down
at 14,000xG for 10 minutes at 4C. Supernatant was moved to a new tube and quantified by
Pierce BCA protein assay kit (23225, Thermo Fisher).

2.15 Measurement of cytokines and chemokines
The levels of TNF-α, IL-6, IFN-γ, IL-2, IL-4, IL-10 and IL-17α were determined
in plasma samples through the Mouse Th1/Th2/Th17 Cytometric Bead Array kit (560485,
BD Biosciences, San Jose, CA). Bead fluorescence was measured using the BD
Biosciences LSRII flow cytometer and analyzed with the accompanying software. Protein
levels of CCL5, CCL11, CCL17, CXCL1, CXCL9, CXCL10, CXCL13, CXCL5, CCL22,
CCL2, CCL3, and CCL4 in tissue and mast cell supernatants were analyzed with the
LEGENDplex Mouse Proinflammatory Chemokine Panel (740007, Biolegend) per the
manufacturer’s instructions. Supernatants were loaded without dilution. 100 micrograms
of tissue lysate were loaded for analysis of chemokine levels in the skin, although final
values displayed in the paper were normalized to picograms per milliliter per microgram
of protein loaded. Bead fluorescence was measured using the BD Biosciences LSRII flow
cytometer and analyzed in the Biolegend LEGENDplex data analysis software.
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2.16 Fibroblast proliferation assay
Fibroblasts were cultured from the skin of C57BL/6J mice as previously described
by Seluanov et al93. After 3 weeks of culture, cells were nearly confluent in a 10cm petri
dish. Media was aspirated off and 3 milliliters of trypsin was added to the dish for 5
minutes. After 5 minutes, cells were scraped off using a sterile scraper and spun down at
350xG for 5 minutes. Cells were resuspended in 6 milliliters and plated equally into a 6
well plate in DMEM + 10% FBS + 1% penicillin/streptomycin. After 4 hours to allow the
cells to adhere, cells were counted on an inverted microscope across 4 fields of view per
well at 200x magnification. At this point, 1ml of mast cell supernatants or fresh media was
added to the 1ml of culture in each well. Cells were counted again 24 hours later, and again
after 48 hours.

2.17 Human tissue samples
All GVHD samples were from patients at the University of Kentucky Markey
Cancer Center who had undergone an allo-HSCT with a subsequent diagnosis of chronic
GVHD. Chart review and sample acquisition was performed by the honest broker of the
University of Kentucky Biospecimen Procurement and Translational Pathology Core and
samples were sectioned from paraffin-embedded tissue. All normal and cGVHD skin
samples were derived from surgical specimens left over from clinical care that were banked
by the UK Biospecimen Procurement Core under a waiver of consent from the UK IRB.
All samples were deidentified and were not able to be linked to patient records by any
investigators involved in the study. As a result of this, the University of Kentucky
Institutional Review Board deemed that these samples did not meet the Department of
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Health and Human Services (DHHS) definition of human subjects or the Food & Drug
Administration’s (FDA) definition of human subjects.

2.18 Figure preparation and statistics
All figures were prepared in GraphPad Prism 6 and 7 (GraphPad, San Diego, CA),
FlowJo V10 (FlowJo Inc., Ashland, OR), or NanoString nSolver (NanoString
Technologies, Seattle, WA) software packages. Experimental data are expressed as means
± standard deviation unless noted otherwise in the figure legend. Differences between two
groups were analyzed by the two-tailed independent t-test. Differences between three or
more groups were analyzed by one-way ANOVA, with a Tukey’s post-hoc multiple
comparisons test to determine the significance between groups. P values ≤0.05 were
considered statistically significant. P value 0.01 to 0.05 = *, P value 0.001 to 0.01 = **, P
value 0.0001 to 0.001 = ***, P value <0.0001 = ****, NS = not significant
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CHAPTER 3. MAST CELLS SURVIVE AND ARE FUNCTIONAL AFTER IONIZING
RADIATION AND CHEMOTHERAPY
3.1

Introduction
The conditioning regimen given to a patient is a key step in the process of HSCT.

In an idealized transplant, this regimen, usually consisting of chemotherapy, radiation, or
a combination of both, serves multiple purposes. First, it ablates the recipient bone marrow,
creating hematologic “space” for the donor stem cells to engraft and grow. Second, it
eliminates recipient-derived immune cells, either in circulation or in the tissues. This
allows the donor immune cells to reconstitute in an environment where they can grow to
maturity properly without undue influence from the host immune system. Lastly,
conditioning also immunosuppresses the recipient; any cells that survive conditioning are
damaged and incapable of mounting an immune response, therefore allowing them to be
cleared by the nascent donor-derived immune system as it reconstitutes from the marrow11.
Crucially, this process allows for engraftment to function properly, as the donor cells would
otherwise be recognized as non-self and cleared by the recipient immune system.
However, not all recipient-derived cells are cleared during conditioning. Cells in
the tissues can sometimes survive, either by virtue of being slowly replicating cells that are
less affected by chemotherapy or by receiving a lesser dose due to their tissue
localization11,30. An example of this is recipient-derived antigen-presenting cells, which are
activated shortly after transplant and present self-antigens to donor immune cells from the
graft which then further activate the APCs, a classic pathophysiology loop in the induction
of acute GVHD. Additionally, incomplete suppression of recipient bone marrow can lead
to long-term chimerism due to continual production of host hematopoietic cells from the
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marrow. These scenarios are acknowledged, but conditioning is still widely considered to
eliminate the vast majority of recipient-derived immune cells94.
In previous studies, mast cells had been shown to be surprisingly resilient to
radiation95. However, most of these studies used lower doses of radiation than are
commonly implemented in pre-HSCT conditioning. Additionally, there is little data on the
effect of chemotherapeutic alkylating agents on mast cells, and what data exists has often
been generated in the context of canine mast cell tumors96. Given the possibility of mast
cells as profibrotic and pathogenic cells in cGVHD, we therefore sought to determine
whether mast cells, in vitro, may be resistant to the types of challenges seen during pretransplant conditioning.

3.2
3.2.1

Results
Mast cells survive exposure to radiation and chemotherapeutic agents
Previous literature by several groups indicated that mast cells might be capable of

surviving high doses of ionizing radiation, such as that used in conditioning prior to
transplant of donor cells64,95,97. To determine this, we derived mast cells ex vivo from
murine bone marrow precursors from both BALB/cJ and C57BL/6J mice. After 4-6 weeks
of culture, these cells displayed morphological similarity to mast cells, and at least 97
percent displayed the characteristic markers of mast cells, FCeR1a/cKit +/+ by flow
cytometry (Figure 3.1).
We then tested the viability and overall number of these cells after they were treated
with either 8.5 or 20 Gy of ionizing radiation. Mast cells from either C57BL/6J or BALB/cJ
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mice showed no change from baseline after 96 hours of culture, implying that mast cells
are highly resistant to cell death induced by ionizing radiation (Figure 3.2). Rather than
total body irradiation (TBI), chemotherapy-based regimens are often used clinically. We
tested whether mast cells could survive a common chemotherapy-based conditioning
regimen of busulfan and cyclophosphamide. We saw that in all groups, using both radiation
and chemotherapeutic agents, mast cell viability was unaffected and cell count increased
after 10 days, implying a low level of cell proliferation. Doses were picked based on
clinically achievable steady-state serum concentrations91,98.
3.2.2

Mast cells are still functional and capable of degranulation after irradiation
Since total body irradiation is the conditioning regimen used in almost all murine

models, we then tested whether mast cells would remain functional after irradiation.
CD107a is a protein involved in vesicle trafficking and function and is expressed on the
inner leaflet of vesicles. After these vesicles dock with the membrane, CD107a is
detectable on the cell surface. Therefore, a greater degree of mast cell degranulation
induces higher CD107a expression99. Degranulation in response to FCeR1a receptor
crosslinking was measured by CD107a expression on the cell surface. Degranulation was
apparent at all doses and was unaffected by ionizing radiation (Figure 3.4).

3.3

Discussion
Our data demonstrating mast cell viability and functionality after conditioning

(Figures 3.1-3.4) confirm several earlier studies showing similar results95,100. However,
while previous work merely showed that mast cells initially survive irradiation, these
experiments expand on this considerably; not only do we show that mast cells survive both
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irradiation and chemotherapeutic agents, but we also show that these challenges leave the
mast cell unaffected in terms of viability, proliferative capacity, or function.
This resistance of mast cells is striking in contrast to many other immune cell types,
which are considered to be depleted during the conditioning phase of allo-HSCT44.
However, MC resistance to chemotherapeutic alkylating agents is perhaps not entirely
surprising. They express high levels of aldehyde dehydrogenase, which is known to inhibit
the activity of alkylating agents, and divide slowly101–103. Yet their ability to survive and
proliferate even after chemotherapy or 20Gy of radiation is itself unexpected. Taken
together, this implies that the mast cell is a conditioning-resistant, mature, immune effector
cell, which remains functional and that has tropism towards selected cGVHD target organs.
These data lend credence to our hypothesis that recipient-derived mast cells may play a
role in the pathogenesis of chronic GVHD.
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Ckit
FCeR1a
Figure 3.1: Mast cells can be cultured ex vivo from murine bone marrow at high purity
Bone marrow was isolated from C57BL/6J mice under sterile conditions. Marrow was
cultured in DMEM media with 10ng/ml IL-3 for at least 4 weeks. Flow cytometry analysis
of bone marrow-derived mast cells after 4-6 weeks of culture, displaying marker expression
characteristic of mast cells and high purity.
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Figure 3.2: Mast cells survive after exposure to ionizing radiation
Cultured mast cells from either C57BL/6J or Balb/CJ mice were exposed to the listed doses
of ionizing radiation. Mast cell viability (A) and count (B) are shown for each day. There
was no significant change from baseline even 96 hr. after irradiation. Graphs are combined
data from 3 independent experiments.
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Figure 3.3: Mast cells survive and proliferate after exposure to ionizing radiation or
chemotherapeutic agents.
Mast cells cultured from C57BL/6J mice were exposed to the listed doses of radiation,
chemotherapeutic agents, or the combination thereof. Radiation exposure was single dose,
and chemotherapeutic agents were dosed prior to treatment and then left in culture.
Viability (A) and cell count (B) were assessed daily. There was no significant change in
viability across any treatment group, while all cell counts increased after ten days. Data
shown is the combination of 2 separate experiments.
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Figure 3.4: Mast cells are still functional after exposure to ionizing radiation
Since irradiation is the conditioning regimen used in most murine models, we then tested
whether mast cells would remain functional after irradiation. Degranulation in response to
FCeR1a receptor crosslinking was measured by CD107a expression on the cell surface
after 4 hours. Degranulation was apparent at all doses and was unaffected by ionizing
radiation (quantified in A, representative flow plots in B).
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CHAPTER 4. MAST CELLS ARE SIGNIFICANT CONTRIBUTORS IN A MURINE
MODEL OF SCLERODERMATOUS DERMAL CHRONIC GRAFT VERSUS
HOST DISEASE
4.1

Introduction
Our previous experiments have demonstrated that mast cells remain viable and

functional after undergoing procedures designed to replicate pre-transplant conditioning in
vitro. However, while this supports the possibility of mast cell involvement in the
pathogenesis of GVHD, it does not tell us anything about what would happen to mast cells
in a more physiological context. To further analyze the role of mast cells in GVHD, in vivo
models are necessary.
The dichotomy of acute vs. chronic GVHD introduces additional complication.
Some cell types have a clearly defined role during pathogenesis of one form of the disease
(such as recipient-derived antigen presenting cells in acute GVHD onset), but their
contribution in other contexts is unknown or unclear. To that end, we attempted to search
for any previous literature that examined mast cells in the course of GVHD. Initial findings
were of great interest; in the 1980’s Henry Claman and others published an article
discussing the disappearance of mast cells during the onset of cGVHD64. While this
initially had a chilling effect on our hypothesis, further reading revealed a follow up study
by the same group. They reported that the mast cells had not, in fact, disappeared, but were
present and had degranulated, making them difficult to detect by the techniques at the
time97. This fit nicely with our hypothesis that mast cells may survive and be active in the
GVHD setting.
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A continued search of previous literature led to Dr. Levi-Schaffer’s body of work,
which focuses on mast cell, eosinophil, and fibroblast interactions, a feedback loop
involving grouping of cells her lab has dubbed the “allergic effector unit” (AEU)104. This
process begins with mast cell activation and leads to eosinophil recruitment and fibroblast
activation, ultimately ending in pathogenic fibrosis throughout the affected organ system,
an outcome that looks similar to fibrotic chronic GVHD. In the early 1990’s, Dr. LeviSchaffer, using Henry Claman’s work as a basis, began to examine the dynamics of mast
cell activation in cGVHD. Using murine mast cells in vitro, she established a system
wherein she would coculture the mast cells with splenic supernatants from mice that had
established cGVHD. These coculture systems induced mast cell activation and
degranulation, implying that something in the splenic environment during cGVHD is
strongly capable of activating mast cells105. Expanding on this, when she isolated
fibroblasts from mice with cGVHD and cocultured them with mast cells, she saw mast cell
proliferation and activation78. Given that we now understand the AEU to begin with mast
cells and end with fibroblast activation, this hinted at a possible feedback loop of mast cell
and fibroblast activation in cGVHD. However, as seminal and striking as these studies
were, they still had not examined the role of mast cells in vivo in cGVHD.
After Dr. Levi-Schaffer’s work, mast cells in GVHD were subject to minimal study
for approximately two decades. At least in part, this was due to a lack of effective models
of mast cell deficiency. However, as better models were developed, the possibilities of this
area of study began to show themselves. In 2013, Leveson-Gower et al. examined mast
cells in the setting of fully MHC-mismatched acute GVHD66. Using mast cell-deficient
mice alongside MC-deficient mice that had mast cells engrafted back in, they examined
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their survival after allogeneic transplant. Mast cell deficiency was found to result in worse
outcomes in an IL-10 dependent mechanism. The authors concluded that mast cells were
immunoregulatory in the acute GVHD setting, especially through mast cell production of
anti-inflammatory IL-10. However, the authors were unable to replicate IL-10 production
by mast cells in vitro, and while the in vivo evidence supports their conclusions, further
study is needed to determine the cytokine milieu which will induce IL-10 from mast cells.
This study was of interest, particularly for its non-canonical role for mast cells as
immunoregulatory cells. Further, where aGVHD is characterized by acute inflammation,
cGVHD can be thought of as a misguided, aberrant, and eventually pathogenic attempt by
the immune system to heal the damage done and downregulate the inflammatory response.
Therefore, we hypothesized that this regulatory mast cell response, helpful in aGVHD,
could eventually result in some of the pathologies seen in cGVHD.
To assess this, we looked for a model of cGVHD that would allow us to use MCdeficient mice as recipients in an allogeneic transplant (allo-MCd) alongside WT mice
(allo-WT)106. The addition of a syngeneic transplant would serve as a negative control for
disease progression. Under these constraints, the only available model of cGVHD was the
LP/J  C57BL/6 model, which displays sclerodermatous skin disease and diffuse
inflammation over 4-12 weeks post-transplant53. Sclerodermatous cGVHD was a good
candidate for mast cell involvement, as multiple prior studies had linked mast cells to skin
fibrosis in other model systems.
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4.2
4.2.1

Results
Skin mast cells were correlated with severely increased cGVHD and skin
pathology after murine allogeneic transplant
We induced cGVHD in vivo using a minor histocompatibility mismatched murine

bone marrow transplant model (LP/J  C57BL/6J)53, illustrated in Figure 4.1. Allogeneic
bone marrow transplants were performed into both wild type C57BL/6J (allo-WT) and
B6.Cg-KitW-sh/HNihrJaeBsmGlliJ mast cell-deficient mice (allo-MCd). Syngeneic
transplant recipients did not develop cGVHD and served as a negative controls. At 7 weeks
post-transplant, 18.75% of the allo-WT group had died, while there were no deaths in either
the syngeneic or the allo-MCd mice (Figure 4.2A). Using a previously-published wholeanimal GVHD scoring system55, we saw significant decreases in GVHD scoring in alloMCd mice as compared to allo-WT mice by week 5 (Figure 4.2B). While this scoring
system was initially designed for acute GVHD, it also assesses skin and fur integrity and
is thus suitable for our model.
The mice were sacrificed and analyzed after week 7 post-transplant. Syngeneic
mice had almost no skin pathology. However, allogeneic transplantation induced severe
skin pathology in WT mice, which was significantly ameliorated in allo-MCd mice, as
scored by an independent, blinded, board-certified pathologist (hematoxylin and eosin
[H+E] staining, Figure 4.3A). In the allo-WT but not the syngeneic or allo-MCd animals,
pathology scores significantly correlated with clinical GVHD scores (Figure 4.3B). In the
lung, small intestine, liver, and colon, there were no significant pathologic differences
between the allogeneic groups (Figure 4.3C). Only mice in the allo-WT group displayed
clinical symptoms consistent with sclerotic chronic GVHD, including scaly skin, hair loss,
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and patchy lesioning44. When skin from these mice was examined histologically by
Masson’s trichrome staining, fibrotic cGVHD was evident only in the allo-WT group,
including excess collagen deposition, hyperkeratosis, epidermal disruption, and significant
increases in dermal thickness107 as shown by representative images and the corresponding
quantification in Figure 4.4. Importantly, no cGVHD was noted in the allo-MCd mice.
4.2.2

Molecular evidence demonstrates a pro-fibrotic phenotype alongside activated
mast cells after allogeneic transplant
We next analyzed RNA extracted from skin of mice from each group by the

NanoString Myeloid Innate Immunity panel or by qPCR for IL21 (not included in the
NanoString panel). Significant increases in expression of genes associated with skin
fibrosis were evident in the allo-WT group, each of which was significantly lowered in the
allo-MCd group (Figure 4.5)57,108. Taken alongside the histologic data, this indicates a mast
cell-dependent induction of fibrosis. Additionally, when skin from all groups was
examined by fluorescent microscopy, mast cells displayed an activated and degranulated
phenotype, but only in the allo-WT group (Figure 4.6).
Since fibroblasts are the main effector cell responsible for collagen deposition and
fibrosis, we assessed whether supernatants from mast cells could affect the proliferation of
fibroblasts109. We isolated and cultured fibroblasts derived from the skin of naïve
C57BL/6J mice for 2-3 weeks. Following trypsinization, these cells were transferred to a
6 well plate. After 4 hours to allow cells to adhere, there were no differences in count
between groups. We then added fresh media or conditioned media from mast cells
stimulated under various conditions to these cultures and counted them after 24 and 48
hours. We saw that after 24 hours, fibroblasts cultured in conditioned media from activated
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mast cells (IgE + antigen + SCF) had grown significantly more than fibroblasts incubated
with conditioned media from unstimulated mast cells or from mast cells incubated with
IgE but without antigen. By 48 hours post-plating, fibroblasts cultured in conditioned
media from activated mast cells showed a significant increase in cell count compared to all
other conditions (Figure 4.7). This indicates that products from activated mast cells can
induce fibroblast proliferation which could lead to increased fibrosis in vivo. This is further
evidence for the AEU feedback loop characterized by Dr. Levi-Schaffer104.
4.2.3

Patients with cGVHD have increased mast cell counts in the skin
To further examine this phenomenon in the context of human patients with

cGVHD, we obtained approval from the University of Kentucky Institutional Review
Board for studies on banked, deidentified human samples (see Chapter 2.17 for details).
We used the University of Kentucky Biospecimen Procurement and Translational
Pathology Shared Resource Facility (BPTP SRF) to identify skin biopsies from allo-HSCT
recipients who were diagnosed with chronic GVHD and where histologic changes were
consistent with dermal graft-versus-host disease. Patient characteristics are included in
Table 4.1. GVHD prophylaxis and antibiotic regimens were unable to be determined from
the available anonymized patient data. Notably, nearly all patient samples had undergone
conditioning using Bu/Cy (busulfan/cyclophosphamide) as used in Figure 3.3. Samples
from 5 cGVHD patients were stained with Masson’s trichrome alongside skin samples
from patients without cGVHD. Epidermal thickness was measured by Masson’s trichrome
staining and found to be increased due to collagen deposition, consistent with cGVHD
symptomology (Figure 4.8A). We identified levels of tryptase-positive cells in the skin by
immunohistochemistry in order to quantify the number of mast cells present in these
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samples. Tryptase-positive cells were primarily located near the dermal-epidermal junction
and were significantly increased in cGVHD patients as compared to normal skin samples
as measured by Aperio (Figure 4.8B). Quantification was verified by a blinded independent
researcher. Representative images for the staining are shown in Figure 4.8C. These data
correlate with our findings that mast cells may be important in the pathogenesis of dermal
chronic graft-versus-host disease.

4.3

Discussion
When assessed in the context of the data from Chapter 3, it is perhaps unsurprising

that there was such a dichotomous difference in cGVHD symptomology in vivo between
the allo-WT and allo-MCd groups in our murine model of allogeneic transplant. Using the
LPJC57BL/6J model of murine cGVHD in both WT C57BL/6J and B6.Cg-KitWsh

/HNihrJaeBsmGlliJ MC-deficient animals, we showed evidence for reductions in whole-

animal GVHD scoring, skin pathology, and in dermal thickness and fibrosis in the alloMCd mice (Figures 4.1-4.4). This correlated with decreases in transcript level of genes
associated with fibrosis in the dermal environment (Figure 4.5)57,108. Additionally, our in
vitro evidence demonstrated that mast cells are capable of producing factors that induce
proliferation in skin-derived fibroblasts, which are responsible for collagen deposition
(Figure 4.6). Mast cells are known to be one of the major sources of fibroblast growth
factor, which could explain this phenomenon83. Additionally, we show that when present
after allogeneic transplant, mast cells display striking evidence of systemic degranulation,
data which fits alongside Henry Claman’s earlier studies64,97.
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Previous work by Leveson-Gower et al. has shown that the presence of mast cells
is beneficial in the context of acute GVHD through mast cell production of antiinflammatory factors, such as IL-1066. However, that study was performed in a
C57BL/6BALB/c model of acute GVHD, where defining characteristics of the disease
include acute inflammation and early alloreactive damage to the tissues, along with rapid
disease onset, progression and mortality from acute GVHD. In contrast, chronic GVHD is
often defined by inappropriate and prolonged inflammation alongside anti-inflammatory
“wound healing” responses and fibrosis110. Therefore, we believe that the mast cell, while
beneficial in the inflammatory phase of aGVHD, ultimately becomes detrimental in
cGVHD through its ongoing anti-inflammatory activities resulting in collagen deposition
and pathogenic fibrosis.
These data fit with a study by Levi-Schaffer et al., which demonstrated that mast
cells are activated by splenic supernatants from mice with cGVHD, as well as their work
showing that fibroblasts from mice with cGVHD enhance proliferation of connective
tissue-derived mast cells78,105. Taken together with our data showing that mast cell products
can stimulate proliferation of fibroblasts (Figure 4.7) this could indicate a positive feedback
loop in cGVHD wherein mast cells and fibroblasts are able to induce proliferation in the
other cell type. In addition, there is a growing body of literature in human and murine
models demonstrating that mast cells and fibroblasts have both direct and indirect
interactions, the result of which is increased collagen deposition and fibrosis89,111–113.
Lastly, we show that patients with dermal manifestations of cGVHD have higher
overall numbers of mast cells in the skin than normal controls (Figure 4.8). This data is
similar to what we observed in our murine model and is suggestive that mast cells may be
60

active and possibly proliferating in human cGVHD. Further studies directly or indirectly
addressing mast cells and correlative biomarkers are warranted as these may assist
physicians in diagnosing and predicting skin cGVHD as well as expanding the options for
treatment.
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Figure 4.1: Transplant layout for experiments to assess the role of mast cells in dermal
manifestations of chronic GVHD
cGVHD was induced in vivo through a minor histocompatibility mismatched murine bone
marrow transplant model (LP/J  C57BL/6J)17, illustrated above. Allogeneic bone
marrow transplants were performed using 850cGy ionizing radiation as conditioning,
followed by bone marrow and splenocyte infusion into both wild type C57BL/6J (allo-WT)
and B6.Cg-KitW-sh/HNihrJaeBsmGlliJ mast cell-deficient mice (allo-MCd). Syngeneic
transplant recipients did not develop cGVHD and served as a negative control.
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B

Figure 4.2: Survival and GVHD scoring of recipient mice after BMT
A: Kaplan-Meier survival curve of syngeneic (n=6), allo-WT (n=14), and allo-MCd (n=16)
groups after transplant. The curves are not significantly different, though the syngeneic and
allo-MCd groups had no deaths, while the allo-WT group had 3 deaths. Data is combined
from two independent transplants. B: Weekly GVHD scoring of syngeneic (n=6), allo-WT
(n=16), and allo-MCd (n=14) groups after transplant. By week 5, there is a significant
reduction in GVHD score in allo-MCd mice as compared to allo-WT mice as measured by
a repeated-measures one-way ANOVA. Error bars are the standard error of the mean
(SEM). P value 0.001 to 0.01 = **, P value <0.0001 = ****.
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B

C

Figure 4.3: Skin pathology scoring was significantly increased in WT but not MCdeficient mice after allogeneic transplant
A: Skin pathology score is significantly decreased in the allo-MCd (n=16) group as
compared to the allo-WT group (n=14). Scoring accounts for damage to the epidermis,
dermis, subcutaneous fat, and hair follicles, as well as inflammatory infiltrate and was
performed by a blinded pathologist. Data is combined from two independent transplants.
B: Whole-animal GVHD scoring significantly correlates with skin pathology scoring. R
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squared and P values were determined by Spearman nonparametric correlation. C: Organ
pathologies in lung, small intestine, colon, and liver were not significantly different
between groups. P value 0.01 to 0.05 = *.
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A

B

Figure 4.4: Skin fibrosis and dermal thickening is evident in allo-WT but not allo-MCd
animals after allogeneic transplant
Representative images (A) and quantification (B) of Masson’s trichrome staining of skin
from syngeneic (n=6), allo-WT (n=16), and allo-MCd (n=14) groups after transplant. Mice
were quantified for dermal thickness according to the height of the blue collagen band
across 10-20 different fields per mouse. Images are mice with dermal thickness closest to
the mean values for each group. Quantification is combined data from two independent
transplants. P value <0.0001 = ****.
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Figure 4.5: Genes associated with dermal fibrosis are significantly upregulated in alloWT animals
NanoString analysis or qPCR (IL21 only) were performed on RNA extracted from skin of
mice after transplant. Significant upregulation of genes associated with dermal fibrosis are
seen in allo-WT animals only. Syngeneic (n=3), allo-WT (n=3), and allo-MCd (n=5) mice.
P value 0.01 to 0.05 = *, P value 0.001 to 0.01 = **, P value 0.0001 to 0.001 = ***, P value
<0.0001 = ****.
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Figure 4.6: Mast cells in the skin of allo-WT but not allo-MCd or syngeneic animals
display evident degranulation
Avidin-Texas Red staining of mast cell granules shows clear evidence of degranulation in
skin from allo-WT animals. Granules are distributed throughout the area surrounding the
cell nuclei (DAPI, blue) in WT animals, shown here, but this phenomenon was not seen in
the other groups.
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Figure 4.7: Supernatants from activated mast cells cause increased proliferation in
fibroblasts
Fibroblasts were isolated from murine skin and expanded. Cells were then disassociated
and replated in plain media or with supernatants from mast cells, noted above. 48 hours
after plating, supernatants from mast cells stimulated with IgE + antigen + 50ng/ml SCF
caused fibroblasts to proliferate significantly more than any other condition, as measured
by cell counting across 5 fields of view. Data is representative of two independent
experiments. P value 0.01 to 0.05 = *.
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Table 4.1: Characteristics of patients used in human sample analysis

Characteristics of patients used in the study were determined based on anonymized data
derived from charts of patients seen for clinical care at the University of Kentucky hospital.
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B

Figure 4.8: Mast cell numbers are increased in the skin of patients with dermal
manifestations of cGVHD
A: Skin biopsies from patients with cGVHD displayed histologic changes consistent with
dermal cGVHD including epidermal thickening as compared to normal controls (normal
controls n=4, cGVHD patients n=5). B: cGVHD patient samples had a significant increase
in tryptase staining as measured by Aperio ImageScope in the dermis as compared to
normal controls (normal controls n=4, cGVHD patients n=5). Representative images of
tryptase immunohistochemistry shown in (C). P value 0.01 to 0.05 = *.
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CHAPTER 5. MAST CELL CHEMOKINE PRODUCTION AND EFFECTOR CELL
RECRUITMENT IS NECESSARY IN SCLERODERMATOUS GRAFT VERSUS
HOST DISEASE
5.1

Introduction
Both acute and chronic GVHD share a root cause: alloreactive donor immune

cells31. It has long been established that complete elimination of donor immune cells from
the graft protects the recipient from GVHD, but at a cost. Without the alloreactivity from
donor-derived immune cells in the graft, patient relapse rates are greatly increased due to
the lack of graft-versus-leukemia effect. Therefore, the standard of care emphasizes a
balance; complete immunosuppression is ineffective due to relapse and so close patient
monitoring is necessary to maximize therapeutic potential while minimizing GVHD.
Aiding clinicians in maintaining this balance are immunosuppressive agents such as
steroids or tacrolimus114.
Since chronic GVHD often takes place subsequent to aGVHD (or after the
timeframe when aGVHD is common), many of the same characteristics visible in late stage
aGVHD are visible27. Of particular relevance to this dissertation is the skin. In dermal
cGVHD, biopsies often show significant collagen deposition and a relatively acellular
dermis. Macrophage and T-cell infiltration is still present, but usually Th2-dominant in
contrast to a proinflammatory Th1 profile seen in aGVHD115. Fibroblasts are abundant.
Overall, the dermal environment is mixed; smoldering inflammation exists alongside
aberrant wound healing responses, leading to a very profibrotic environment.
Murine models of sclerodermatous cGVHD, such as the LP/J  C57BL/6 model
used in our studies, display similar attributes. Immune infiltrate to the skin can be slightly
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greater than would be seen in human patients, but the end results (collagen deposition, skin
thickening, and pathogenic fibrosis) are largely the same53. This is driven largely by
chemokine production from tissue-resident cells116. While macrophages are the canonical
drivers of chemokine production, we wanted to know whether mast cells would also be
capable of enhancing or driving these responses. Since our findings in previous chapters
demonstrate a difference in GVHD scoring and skin pathology between WT and MCdeficient mice, we next decided to explore the functional role of mast cells in the skin.

5.2
5.2.1

Results
Proinflammatory chemokine expression is significantly increased in the skin of
WT but not mast cell-deficient mice after allogeneic transplant
Skin from animals from each group was analyzed using the NanoString Myeloid

Innate Immunity panel. When we looked at the subset of genes overexpressed in allo-WT
vs. allo-MCd by PANTHER pathway analysis117, we found only one pathway to be
statistically significant, an approximately 5-fold enrichment for the “Inflammation
mediated by chemokine and cytokine signaling pathway” (PANTHER pathway number
P00031, data not shown). Further analysis was performed using the NanoString nSolver
software which clusters genes by pre-annotated pathways. Sorting on “Chemokine
signaling genes,” heatmap analysis demonstrated an overall trend towards increased
dermal expression of genes involved in these pathways in allo-WT mice, with lower
expression in allo-MCd mice (Figure 5.1). We then examined expression of specific
chemokine transcripts. CCL2, CCL3/CCL4 (which encode MIP-1a and MIP-1b,
respectively), and CCL5 all demonstrated significant upregulation of transcript in the skin
in allo-WT mice (Figure 5.2A). When we measured protein levels of these chemokines by
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cytometric bead array, we saw an extremely similar expression pattern, with all 4
chemokines upregulated in allo-WT, while syngeneic and allo-MCd were not significantly
different (Figure 5.2B). Intriguingly, the levels of these chemokines in the allo-WT group
were all significantly correlated with their overall GVHD score (Figure 5.3). All of these
chemokines can be chemotactic for T-cells, the canonical GVHD effector cell118,119.
Additionally, they are capable of recruiting monocytes, macrophages, or other myeloid
cells, many of which are implicated in cGVHD pathogenesis and fibrotic disease.
5.2.2

Immune infiltration and activation to the skin is ameliorated by mast cell
deficiency
Given the inflammation and increased chemokines evident in the skin of our allo-

WT mice, we wanted to determine whether this resulted in increased immune infiltration
and tissue damage. Indeed, when we examined H+E-stained skin sections from allo-WT
mice, epidermal dysregulation and an obvious dermal immune infiltrate was visible (Figure
5.4A, quantified in Figure 5.4B). Animals from the syngeneic and allo-MCd groups
displayed equally low levels of immune infiltrate. The immune infiltrate was characterized
as to its hematopoietic lineage and was found to be predominantly lymphocytic in all three
groups (Figure 5.5). Accordingly, there was no significant difference across all groups in
eosinophil or neutrophil count in H+E-stained skin sections, nor was there a difference in
CD19 transcript by qPCR (data not shown). All characterization and counting on H+E
slides were performed by an independent, board-certified pathologist.
T-cells in the skin, as measured by immunohistochemistry against CD3, were
lessened in allo-MCd compared to allo-WT animals (Figure 5.6A). This slight but
significant increase in cellularity was seen alongside increased gene expression of markers
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of T-cell activation including CD69 and VAV1, as well as markers of costimulation such
as CD80 and CD86 (Figure 5.6B). It seems that while the level of T-cell infiltration is not
hugely different, activation and the costimulatory milieu in the dermal environment may
enhance their effects. With this evident inflammatory infiltrate, and as the PANTHER
analysis had also implicated inflammatory cytokine signaling in the skin, we wanted to
analyze dermal levels of inflammatory cytokines that are often expressed by T-cells.
Inflammatory cytokines were found to be expressed at very low levels in skin and were
largely unchanged between groups (Figure 5.7). Of note, while the overall levels of
cytokines were extremely low, the only cytokines that were differentially expressed
between groups were IFN-gamma and IL-4, canonical Th1 and Th2 cytokines,
respectively. This implies that the T-cell infiltrate in the skin is not of a homogenous
phenotype but has mixed Th1 and Th2 potential.
5.2.3

Mast cell production of chemokines is amenable to therapeutic intervention by
drugs commonly used to treat sclerodermatous cGVHD
Mast cells are known to be able to produce a wide variety of mediators, as reviewed

excellently by Mukai et al 75. As shown in Figure 5.1, chemokine production seems to be
a major factor in the pathogenesis of sclerodermatous GVHD in this model. Therefore, we
wanted to test whether mast cells were capable of producing these same cytokines, assayed
ex vivo using bone marrow-derived mast cells cultured from C57BL/6J mice.
Indeed, we saw that upon stimulation with multiple methods of mast cell activation
(IgE/antigen crosslinking or IgE/antigen + IL-33), mast cells produced significant amounts
of CCL2, CCL3, and CCL4. Currently, there isonly FDA-approved drug for cGVHD,
ibrutinib, a BTK inhibitor. Also used in cGVHD although currently in late-phase trials,
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ruxolitinib, a Jak1/Jak2 inhibitor, has also been used by physicians with promising results.
We examined whether these treatments, as well imatinib and fingolimod, other
experimental drugs for cGVHD or mast cell diseases would affect mast cell chemokine
production. Indeed, ibrutinib and ruxolitinib reduced mast cell production of these
chemokines in a dose-dependent manner (Figure 5.8, 5.9). Treatment with imatinib or
fingolimod did not reduce mast cell chemokine production even at the highest doses tested,
and dosing with all drugs tested had no effect on cell viability (data not shown). While
CCL5 was the other chemokine significantly upregulated in the skin of allo-WT mice
(Figure 5.2), we saw no CCL5 production from mast cells in this context, though previous
papers from our group have pointed out donor-derived T-cells as the primary producers of
CCL5 in the post-transplant setting68.

5.3

Discussion
As has been extensively reported by our group and others, chemokine production

and effector cell infiltration are key instigators in both acute and chronic GVHD. The
relative contributions of these processes may vary depending on disease status, tissue type,
time post-transplant, and many other factors. Ultimately, it is nonetheless clear that
recruitment of alloreactive cells to the tissues is a major initiating factor in GVHD
pathogenesis.
In our murine model, we see several of these phenomena recapitulated, which lends
further credence to its effectiveness as a model of sclerodermatous chronic GVHD. As we
discussed in Chapter 4, key characteristics of dermal cGVHD are present, including skin
thickening due to excessive collagen deposition. Additionally, genetic markers of fibrosis

76

are upregulated, and we see that mast cells display an activated phenotype. We also show
that activated mast cells are capable of inducing fibroblast proliferation, allowing for one
plausible mechanism for the increase in collagen deposition.
However, beyond the physical characteristics of GVHD, we also see a genetic and
protein signature that fits what we know of the disease. Using RNA isolated from the skin
of mice post-transplant, we ran a NanoString Myeloid Innate Immunity panel. This profiled
the transcript abundance of more than seven hundred genes involved in myeloid immunity.
We then examined this dataset for broad trends using PANTHER pathway analysis. The
only pathway that was upregulated was “Inflammation mediated by chemokine and
cytokine signaling,” which allowed for the possibility of significant dysregulation of
signaling pathways using these molecules.
Indeed, once we examined this dataset more deeply, we saw a strong signature of
chemokine production upregulated in allo-WT but not allo-MCd mice (Figure 5.1). We
further saw that the allo-WT animals had significant increases in transcript and protein
levels of specific chemokines (CCL2, CCL3, CCL4, and CCL5) that can recruit canonical
cGVHD effector cells (Figure 5.2). Levels of these chemokines significantly correlated
with our whole-animal GVHD scoring (Figure 5.3). Additionally, the skin of allo-WT mice
had increased tissue damage and a primarily lymphocytic immune infiltrate (Figure 5.4).
We also showed a concomitant increase in T-cell number by immunohistochemistry,
alongside data demonstrating increased levels of genes involved in T-cell activation and
signaling (Figure 5.5). However, despite this overactivation, the levels of many T-cell
cytokines were shown to not significantly differ between groups in Figure 5.7. We believe
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this is due to the relatively small difference in number of T-cells alongside the possibility
that these cytokines are produced by other cell types, such as macrophages or mast cells.
Importantly, all these changes were ameliorated by mast cell-deficiency. Given the
mast cell’s well-known role as a “sentry cell120,” it seems that in the context of cGVHD
pathogenesis they may be necessary for initial recruitment of inflammatory cells which
then cause a feedback loop of further inflammation and immune recruitment. Additionally,
they may have more direct effects through their impact on fibroblast proliferation. We also
show that mast cells are capable of production of many of the chemokines that are
upregulated in the allo-WT animals (Figure 5.8A, B, C, columns 1, 2, 6).
Ibrutinib is a combined BTK/ITK inhibitor known to be efficacious in treatment of
murine and human cGVHD, for which it is currently the only FDA-approved drug34,121.
The Jak1/Jak2 inhibitor, ruxolitinib has been effective in case studies and is currently in
Phase 2 and 3 clinical trials for use in steroid-refractory cGVHD. Additionally, its
molecular targets are heavily involved in mediation of cytokine and chemokine
signaling72,122,123. Mast cells express many of the signaling molecules targeted by these
drugs, and we therefore investigated whether chemokine production would be inhibited
when treated with ibrutinib or ruxolitinib124,125. Indeed, we found a dose-dependent
decrease in production of CCL2, CCL3, and CCL4 when treated with ibrutinib and
ruxolitinib (Figures 5.8, 5.9). This phenomenon was not seen in cells treated with imatinib
or fingolimod, which is unsurprising given the lack of exogenous S1P or SCF in the assay
(data not shown). Given the overexpression of these same chemokines in the skin of the
allo-WT vs. allo-MCd mice (Figure 5.2) and the reduction in skin symptomology of
patients treated with ibrutinib and ruxolitinib122, it may be that inhibition of mast cell
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chemokine production is a component of the mechanism by which these inhibitors are
clinically efficacious.
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Figure 5.1: Genes involved in chemokine signaling are increased in allo-WT mice
Heatmap analysis showing lowered expression of chemokine signaling genes in RNA
extracted from the skin of allo-MCd animals compared to allo-WT animals as measured
by NanoString. Heatmaps and gene pathway annotations were generated using NanoString
nSolver software.
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B

Figure 5.2: Mast cell deficiency results in decreased transcript and protein levels of
chemokines in the skin of mice after allogeneic transplant
A: Transcript as measured by NanoString, and B: protein levels of chemokines are
upregulated in the skin of allo-WT mice, while syngeneic mice and allo-MCd mice are not
significantly different.

(syngeneic n=6, allo-WT n=6, and allo-MCd n=8, data are

combined from two independent transplants). Protein levels were measured by
LEGENDplex Chemokine Cytometric Bead Array kit. All NanoString data displayed is
from syngeneic (n=3), allo-WT (n=3), and allo-MCd (n=5) mice. P value 0.01 to 0.05 = *,
P value 0.001 to 0.01 = **.

81

Figure 5.3: Chemokine levels correlate with overall GVHD scoring
Protein levels of CCL2, CCL3, CCL4, and CCL5 all significantly correlate with wholeanimal GVHD scoring. R squared and P values were determined by Spearman
nonparametric correlation. P value 0.01 to 0.05 = *.

82

A

B

Figure 5.4: Immune infiltration to the skin is ameliorated by mast cell deficiency
A: Representative images from H+E staining show an increased immune infiltrate and
tissue damage in skin from allo-WT animals, while syngeneic and allo-MCd animals have
a similar phenotype. In allo-WT animals, epidermal dysregulation and an obvious dermal
immune infiltrate is visible. B: Quantification of immune infiltrates in the skin. P value
0.001 to 0.01 = **.

u
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Figure 5.5: Immune infiltrate to the skin is primarily lymphocytic
The immune infiltrate to the skin after allogeneic transplant was characterized by a blinded,
board-certified pathologist as to its hematopoietic lineage and was found to be
predominantly lymphocytic in all three groups.
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Figure 5.6: T-cell counts and genes related to T-cell activation are significantly increased
in WT but not MC-deficient animals after allogeneic transplant
A: Immunohistochemistry against CD3 demonstrates a significant increase in Tcell infiltration in the skin of allo-WT as compared to allo-MCd animals. Slides were
digitally scanned using the Aperio ScanScope XT, then quantified for DAB chromogen
staining across the whole tissue using the Positive Pixel Count V9 algorithm. B: Heatmap
and gene-level analysis demonstrates significant increases in genes involved in the T-cell
activation pathway in allo-WT as compared to allo-MCd animals as measured by
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NanoString. This indicates that despite a slight but significant increase in T-cells, activation
status of those cells widely differs between groups. Heatmaps and gene pathway
annotations were generated using NanoString nSolver software. NanoString data displayed
is from syngeneic (n=3), allo-WT (n=3), and allo-MCd (n=5) mice. P value 0.01 to 0.05 =
*, P value 0.001 to 0.01 = **, P value 0.0001 to 0.001 = ***, P value <0.0001 = ****.
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Figure 5.7: Cytokine levels in the skin are expressed at low levels but reveal mixed
Th1/Th2 responses
Protein levels of cytokines characteristic of Th1 and Th2 responses were measured in the
skin. All cytokines were expressed at low levels. IL-6 and TNF-alpha were not significantly
different between groups, but IL-4 (a Th2 cytokine) and IFN-gamma (a Th1 cytokine) were
upregulated in WT but not MC-deficient mice after allogeneic transplant, indicative of a
mixed response. P value 0.001 to 0.01 = **, NS = not significant.
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Figure 5.8: Mast cells produce chemokines upon stimulation, production of which is
blocked by ibrutinib, a drug used in treatment of cGVHD
Mast cells produce high levels of A: CCL2, B: CCL3, and C: CCL4 upon
stimulation with IgE + antigen or IgE + antigen + IL-33 (column 1 vs. columns 2 and 6).
Production of these chemokines is inhibited by treatment with ibrutinib in a dosedependent manner. Results shown are representative of 2-4 independent assays. Error bars
are the SD of technical replicates. Chemokine assays were performed using the
LEGENDplex Inflammatory Chemokine Assay kit, which measures levels of 13
chemokines. Mast cells did not produce significant amounts of CCL5, CCL11, CCL17,
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CXCL1, CXCL9, CXCL10, CXCL13, CXCL5, or CCL22 (data not shown). P value 0.01
to 0.05 = *, P value 0.0001 to 0.001 = ***, P value <0.0001 = ****.
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Figure 5.9: Ruxolitinib also blocks mast cell chemokine production
Mast cells produce high levels of A: CCL2, B: CCL3, and C: CCL4 upon
stimulation with IgE + antigen or IgE + antigen + IL-33 (column 1 vs. columns 2 and 6).
Production of these chemokines is inhibited by treatment with ibrutinib in a dosedependent manner. Results shown are representative of 2-4 independent assays. Error bars
are the SD of technical replicates. Chemokine assays were performed using the
LEGENDplex Inflammatory Chemokine Assay kit, which measures levels of 13
chemokines. Mast cells did not produce significant amounts of CCL5, CCL11, CCL17,
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CXCL1, CXCL9, CXCL10, CXCL13, CXCL5, or CCL22 (data not shown). P value 0.01
to 0.05 = *, P value 0.001 to 0.01 = **, P value 0.0001 to 0.001 = ***, P value <0.0001 =
****, NS = not significant.

91

CHAPTER 6. MAST CELL ORIGIN AND ACTIVATION IN THE POSTTRANSPLANT ENVIRONMENT
6.1

Introduction
Our data thus far has demonstrated that mast cells are strongly conditioning-

resistant cells that may be capable of surviving in the post-transplant environment.
Additionally, we have seen in our murine model that genetic deletion of mast cells in the
allo-MCd group significantly reduces skin manifestations of dermal cGVHD, including
collagen deposition, inflammation, chemokine production, and immune cell infiltration.
However, while mast cell deficiency provides a plausible mechanism, we recognize that
these symptoms could be secondary effects.
When pondering the role of mast cells in initiating these processes, several
questions immediately arise. Primarily, do mast cells survive conditioning and the posttransplant environment in vivo? Can mast cell deficient mice, when transplanted with WT
bone marrow, have mast cells reconstitute to the tissues, and what is the time scale of this
process? Would chemotherapy vs. TBI-based conditioning differentially affect the
recipient mast cell populations? And lastly, when recipient-derived mast cells are
eliminated, is that through conditioning or elimination by alloreactive donor cells?
Some of this can be answered through the literature. Mast cells are known to be
long-lived, surviving months or even years once mature126, so it is very possible that they
play a role in the relatively late onset of cGVHD. Henry Claman’s work on this topic in
the 1980’s showed that mast cells do not disappear but are activated and degranulated
during GVHD onset64,97. Adding to this, in a recent study, Ustun et al. reported that patients
with increased severity of gut aGVHD had fewer tissue-resident mast cells127. This implies
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that these mast cells may be recipient-derived, having survived conditioning, and are
subsequently eliminated by the increased influx of alloreactive cells during severe aGVHD.
It is also known that mast cells are capable of reconstituting to the tissues of genetically
mast cell-deficient mice when these mice are engrafted with WT marrow or mature mast
cells, although this process took at least 12 weeks106.
Based on this evidence, we examined our LP/J  C57BL/6 murine model of
sclerodermatous cGVHD. If there was complete elimination of mast cells through
conditioning and masts cell had not regenerated from wildtype bone marrow, neither our
syngeneic, allo-WT, or allo-MCd groups would still have mast cells. Conversely, if mast
cells survive conditioning but are eliminated quickly by alloreactive cells and are
regenerated from wildtype bone marrow, then we would see mast cells only in the
syngeneic group. Lastly, if recipient mast cells survive conditioning and alloreactive cell
elimination, but mast cells do not reconstitute from the marrow, we would see them in
syngeneic and allo-WT, but not our allo-MCd groups.
While this experiment can hint at mast cell survival after transplant, it is not
designed solely to answer this question and therefore our conclusions would lack rigor, in
addition to only lasting 7 weeks. Therefore, we designed a syngeneic transplant wherein
we would engraft HSCs from MC-deficient mice into a WT recipient. In this model, no
mast cells will ever reconstitute from the marrow, and any mast cells present can
definitively be shown to be recipient derived. For this experiment, we planned 3 time
points, 60, 90, and 120 days.
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6.2
6.2.1

Results
Recipient mast cells in WT animals may survive conditioning and proliferate after
allogeneic transplant
During a bone marrow transplant, the donor stem cells reconstitute and fill the role

previously played by the recipient bone marrow. Among these roles are hematopoiesis of
lymphoid and myeloid immune subsets, mast cells included128. Ex vivo, we have shown
that mast cells can survive radiation and chemotherapy, but we wanted to determine if mast
cells were still present post-transplant in vivo; in addition to radiation, recipient-derived
mast cells could also be eliminated by alloreactive donor T-cells. Therefore, we used
histochemical and fluorescent methods to examine tissue sites where mast cells are tropic,
including skin, ear, and trachea, as well as other GVHD target organs (small intestine, lung
and liver).
In the first set of experiments, seven weeks after transplant, organ tissue was stained
with toluidine blue and mast cells were counted per high-power field (400x). Skin, ear, and
tracheal tissue showed a similar pattern, with low numbers of mast cells in syngeneic
animals, higher numbers in allo-WT animals, and low-to-undetectable levels of mast cells
in allo-MCd animals (Figures 6.1, 6.2). To confirm the identity of the toluidine bluepositive cells, we stained skin slides with avidin conjugated to the Texas Red fluorophore
and counted the number of stained cells per high-power field. Avidin has been shown to
stain mast cells in a biotin-independent manner129,130 and skin/ear sections from each
animal showed similar numbers and distribution in the tissue (Figure 6.3). In small
intestine, lung, and liver, mast cell numbers were low-to-undetectable and there were no
differences between groups (data not shown). Findings were verified by a blinded,
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independent researcher. To confirm our finding in the skin, we returned to our NanoString
data set, where we found that mast cell-specific genes including chymase, tryptase,
FCeR1a, and Cpa3 were expressed at extremely low levels in the skin of allo-MCd mice
(Figure 6.4).
6.2.2

Recipient mast cells are not eliminated by chemotherapy or irradiation-based
conditioning and are maintained after syngeneic transplant
We next performed a syngeneic transplant designed to identify recipient-derived

mast cells that survive conditioning by either chemotherapy or TBI. The transplant layout
is shown in Figure 6.5. At 60, 90, and 120 days, we sacrificed mice and took skin and ear
biopsies to examine mast cell numbers. When stained with avidin, we saw that there were
minor reductions in mast cell counts in both skin and ear when transplanted using either
chemotherapy or TBI-based conditioning. However, we saw that mast cells ultimately
survived over a long period of time, as mast cell numbers in the tissues were maintained at
approximately fifty percent or more of the values seen at day 60, even out to 120 days
(Figure 6.6).
We confirmed this finding with toluidine blue staining of skin and ear sections,
which not only showed the same trend and similar values (Figure 6.7A), but a significant
correlation between avidin- and toluidine blue-positive cells (Figure 6.7B). Representative
images of toluidine blue-stained skin and ear tissue from mice sacrificed at day 120 clearly
show the presence of mast cells even at this late timepoint post-transplant (Figure 6.8).
Taken together, these data definitively show that mast cells are capable of surviving
conditioning and the post-transplant environment, though future studies will need to
confirm these findings in the setting of an allogeneic transplant.
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6.3

Discussion
In this allogeneic LP/J  C57BL/6 transplant, our data has clearly demonstrated

that mast cell-deficiency was maintained in the allo-MCd group, while the syngeneic and
allo-WT groups still had significant numbers of mast cells, as measured by toluidine blue
and avidin staining (Figure 6.1-6.3). This finding was confirmed by transcript-level
analysis of mast cell-specific genes (Figure 6.4). The extremely low numbers of mast cells
in the allo-MCd compared to our allo-WT and syngeneic groups, even 7 weeks posttransplant, imply that mast cells were unable to fully reconstitute from the bone marrow
into their tissue niche. Given that mast cells are known to be capable of reconstitution to
skin and ear within 12 weeks post-bone marrow transplant106, we believe that the mast
cells in the allo-WT and syngeneic groups may be recipient-derived. However, our model
did not allow for definitive recipient vs. donor differentiation and there may be other factors
driving this disparity in mast cell numbers.
Therefore, we performed a syngeneic transplant designed to definitively determine
whether recipient-derived cells could survive conditioning, and for what length of time
they would survive post-transplant (Figure 6.5). At 60 days, mast cells were still present,
as determined by both avidin and toluidine blue staining. When we examined the 90 and
120-day timepoints, we saw that while there were mild reductions in mast cell numbers in
the tissue, we could definitively show that many mast cells survive even 120 days after
transplant (Figure 6.6-6.7, representative images in Figure 6.8). This data shows that mast
cells do indeed survive after transplant and could therefore be capable of inducing many of
the pathologies seen in Chapter 4. Expanding a similar set of experiments into allogeneic
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transplant will allow us to determine the degree of alloreactive elimination of mast cells
that may be taking place in the post-transplant environment.
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Figure 6.1: Toluidine blue staining reveals increased levels of mast cells in the skin of
WT recipients and no reconstitution of mast cells in the allo-MCd group after allogeneic
bone marrow transplant.
Mast cell counts and toluidine blue-stained representative images in the skin of syngeneic
(n=6), allo-WT (n=16), and allo-MCd (n=14) animals. Mast cell counts per high-power
field (400x) are displayed alongside images from animals whose mast cell count was
nearest the mean value for the group. Mast cells (arrows) were denoted by metachromatic
staining and granular appearance. At 7 weeks post-transplant, mast cells had not
reconstituted from the LP/J marrow, implying that recipient mast cells may have survived
conditioning. P value 0.01 to 0.05 = *, P value <0.0001 = ****.
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Figure 6.2: Mast cell deficiency was maintained in the allo-MCd group in other tissues
Mast cell counts and toluidine blue-stained representative images in the skin of syngeneic
(n=6), allo-WT (n=16), and allo-MCd (n=14) animals. Mast cell counts per high-power
field (400x) are displayed alongside images from animals whose mast cell count was
nearest the mean value for the group. Mast cells (arrows) were denoted by metachromatic
staining and granular appearance. Ear and trachea are two tissues where mast cells are
normally present, and the trends visible in Figure 6.1 hold true; mast cells are increased in
WT recipients but have not reconstituted from the marrow in the allo-MCd group. P value
0.01 to 0.05 = *, P value 0.001 to 0.01 = **, P value <0.0001 = ****.
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Figure 6.3: Avidin staining of mast cell granules confirms our toluidine blue findings
Avidin conjugated to the Texas Red fluorophore specifically binds mast cell granules. Mast
cell counts and avidin-stained representative images in the skin of syngeneic (n=6), alloWT (n=16), and allo-MCd (n=14) animals. Mast cell counts per high-power field (400x)
are displayed alongside images from animals whose mast cell count was nearest the mean
value for the group. We confirmed our previous findings using this alternate method.
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Figure 6.4: Mast cell-specific genes are decreased in the skin of allo-MCd mice
Levels of mast cell-specific genes in the skin are significantly lowered in allo-MCd mice.
Data displayed is from syngeneic (n=3), allo-WT (n=3), and allo-MCd (n=5) mice, as
measured by NanoString analysis. P value 0.01 to 0.05 = *, P value 0.001 to 0.01 = **.
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Figure 6.5: Layout of a transplant to determine if recipient mast cells survive
conditioning
We performed a syngeneic transplant using MC-deficient mice as donors. In this way, no
mast cells will ever reconstitute from the marrow; therefore, any mast cells present in the
tissues will be recipient-derived cells. For conditioning, we used both TBI and
busulfan/cyclophosphamide-based chemotherapy to better recapitulate the more common
clinical utilization. Analysis was performed at 60, 90, and 120 days post-transplant.

102

Figure 6.6: Recipient mast cells survive conditioning and the post-transplant environment
Tissue from mice having undergone a syngeneic transplant with either chemotherapy or
radiation-based conditioning was removed, fixed, and stained with avidin for mast cell
granules. Mast cells were still present, although reduced, in skin and ear, even out to 120
days post-transplant. P value 0.01 to 0.05 = *, P value 0.001 to 0.01 = **, NS = not
significant.
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Figure 6.7: Toluidine blue staining confirms the survival of recipient mast cells
A: Staining with toluidine blue confirmed our findings from our avidin-stained sections.
Recipient mast cells are present, although reduced, out to 120 days in skin and ear, across
both chemotherapy and radiation groups. B: Additionally, toluidine blue and avidin
staining demonstrated a high degree of correspondence between the two stains. P value
0.01 to 0.05 = *, P value 0.001 to 0.01 = **, NS = not significant.
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Figure 6.8: Representative images of toluidine blue staining at 120 days post-transplant
Toluidine blue staining of 120-day skin and ear sections (400x) reveals the presence of
mast cells in skin and ear tissue
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CHAPTER 7. OVERALL DISCUSSION
Hematopoietic stem cell transplant (HSCT) is a potentially curative therapy for
many leukemias, lymphomas, metabolic disorders, or inborn defects of hematopoiesis.
While autologous and syngeneic HSCTs allow for a minimization of disease burden prior
to treatment, they also run the risk of increased relapse of primary disease. For this reason,
allogeneic HSCT is often indicated where the primary disease is particularly aggressive,
such as in acute myeloid leukemia20. In allogeneic HSCT, the alloreactive donor-derived
immune cells recognize and destroy the residual cancer cells, an effect known as the graftversus-leukemia effect26.
However, these same alloreactive donor immune cells can also respond against host
tissues, causing both focal and diffuse damage across multiple organ systems, a
phenomenon known as graft-versus-host disease (GVHD). GVHD can range in outcome
from mild to lethal and it is the single largest barrier to widespread therapeutic use of alloHSCT. While certain immune subsets are well-understood for their role in GVHD
pathogenesis, targeting these often involves broad-spectrum immunosuppression. This
treatment is not always tolerable for patients, especially in the long-term, and can often
lead to increases in primary disease relapse or potentially lethal infections42.
The current understanding of the pathogenesis of GVHD has therefore been
insufficient to prevent or treat GVHD in some patients, many of whom can become
refractory to long-term steroids or suffer other debilitating side effects114. Broadly, my
research interests upon joining the lab of Dr. Gerhard Hildebrandt were to search for factors
that initiate and maintain GVHD that may be targetable outside the context of
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immunosuppression. Over the course of my graduate work, these have narrowed and
matured into the subject of this dissertation; the role of mast cells in the pathogenesis of
chronic graft-versus-host disease.
My interest in mast cells was initially piqued by work from Henry Claman, a
seminal immunologist. In 1985, he described the disappearance of mast cells from Balb/C
mice after irradiation and injection of B10.D2 marrow64. This is now established as a model
of sclerodermatous cGVHD but had not been extensively explored at the time. Indeed,
Claman’s use of this model was predicated on its utility as a model of progressive
scleroderma, a phenomenon that was only poorly explicable at the time.
While this mast cell disappearance was not unexpected given the high dose of
irradiation (9 Gy) and the paradigm of host cell elimination during conditioning, Claman
was nonetheless unsure of why it took place. He hypothesized that mast cells may not be
eliminated, but rather degranulated, and therefore largely invisible to the staining methods
of the time. In 1986, he followed up on this hypothesis, demonstrating that mast cells did
in fact disappear from skin staining, but they were not eliminated. When examined by
ultrastructural analysis via electron microscopy, mast cells were clearly still present, albeit
degranulated. Claman referred to these as “phantom mast cells,” and demonstrated that
they showed an activated phenotype and were slowly rebuilding their granule contents97.
Looking back at these studies from the span of several decades, it is clear that there
was more to this story than Claman initially suspected. Given many of the characteristics
seen, I thought that these studies may hint at the possibility of some GVHD biology that
had been understudied. The degranulation of mast cells early in the onset of GVHD
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symptoms allows for a convenient trigger for the initial inflammatory cascade, which can
then be further propagated in the context of the alloreactive feedback loop known to exist
in acute GVHD. Further, the fact that skin mast cells degranulate and rebuild their granule
contents rather than merely disappearing allows for the possibility that recipient-derived
mast cells have survived conditioning, although these studies were too nonspecific to
rigorously answer that question. Additionally, if these mast cells are resistant to irradiation,
is it possible that they may also survive other forms of conditioning, such as chemotherapybased regimens? Lastly, given this activated mast cell phenotype alongside the clinical
evidence of scleroderma, is it possible that mast cells are important in the progression of
this disease?
The number of questions raised by these studies speaks to Henry Claman’s
propensity for addressing the fundamental biology behind the immune system. While he is
better known for his work establishing the basis of T- and B-cell cooperation in antibody
production, he was also an allergist and mast cells were a cell type he understood well. I
would be remiss to continue further in this dissertation without acknowledging that his
work truly underlies my own, and that the clarity and structure of his papers in the 19851986 period allowed for more straightforward follow up studies than would have otherwise
been possible.
However, for several years after this work, the study of mast cells in GVHD
pathogenesis languished. Interest was revived by Francesca Levi-Schaffer in her work with
Henry Claman. While Claman noted the activated mast cell phenotype, Levi-Schaffer dug
further into the mechanism. She discovered that supernatants from splenic cells isolated
from mice with GVHD strongly activated mast cells, in contrast to supernatants from
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healthy mice105. This demonstrates that the donor immune system is capable of producing
factors that induce mast cell activation. She also showed that mast cell co-culture with
fibroblasts isolated from mice with GVHD induced mast cell proliferation78, although both
of these studies were entirely in vitro.
Since Dr. Levi-Schaffer’s work in the early 1990’s, there had been few notable
studies on the topic until 2013, when Leveson-Gower and Robert Negrin published on an
immunomodulatory role for mast cells during the onset of acute GVHD. They used a fully
MHC-mismatched model of GVHD and showed that the absence of mast cells led to
significant increases in GVHD severity compared to WT mice66. However, this
phenomenon was at least partially dependent on IL-10 production by mast cells.
While at first glance, this immunomodulatory role seems contradictory to previous
experiments, it is in fact of great interest. Mast cells are a cell type heavily involved in
allergy, which is notoriously skewed towards Type 2 or Th2 immunity99. Therefore, mast
cell production of IL-10, a Th2 cytokine, fits with their previously understood role.
Additionally, while aGVHD is known for its inflammatory (Type 1) nature, cGVHD tends
to be much more dominated by Type 2 responses. Therefore, an immunomodulatory mast
cell, while initially helpful in the burst of inflammation accompanying aGVHD onset, may
continue to act in a Type 2 manner; aberrant and prolonged Type 2 responses are known
to result in pathogenic fibrosis similar to that seen in cGVHD85.
All of this prior work led us to examine mast cells in the context of chronic GVHD
using more modern methods. In the course of planning for these experiments, we came to
wonder whether it would be best to examine the impact of mast cells derived from donor

109

or from recipient. We therefore established an ex vivo system (Figure 3.1) wherein we
could test mast cell survival after exposure to various agents used in pre-transplant
conditioning. If the mast cells immediately died after exposure, it would lend credence to
the theory that donor-derived mast cells reconstituted quickly from the bone marrow.
However, if mast cells survived this challenge, it would imply that they may be capable of
surviving conditioning, and that recipient-derived mast cells may still be capable of
exerting their effects on the surrounding tissue during GVHD onset.
When we exposed mast cells to the same radiation source and dose (Cesium, 8.5Gy)
used in conditioning for the LP/J  C567BL/6 model, we saw that they had no change in
cellular number or viability after 96 hours. Indeed, even at 20Gy, a supralethal dose initially
intended as a positive control for cell death, mast cells continued to have no reduction in
cell count or viability (Figure 3.2). However, 96 hours after exposure does not capture the
time frame usually seen in aGVHD onset (approximately 7 days) and this experiment did
not take into account one of the most common myeloablative conditioning regimens in
clinical use, busulfan/cyclophosphamide (Bu/Cy). Therefore, we repeated this assay with
exposure to both TBI and Bu/Cy and measured out to 10 days. Again, we saw no decrease
in cell count or viability. Indeed, mast cell number actually increased relative to day 0 of
treatment across all groups, possibly indicative of cell proliferation (Figure 3.3).
However, this assay merely tells us that mast cells may survive conditioning; it
answers nothing about mast cell functionality. Since the majority of murine GVHD models
use TBI for conditioning, we examined mast cell expression of CD107a, a marker of
cellular degranulation, after exposure to 8.5 and 20Gy of radiation. We saw that at both
doses, mast cells were still capable of degranulation at levels no different than unirradiated
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controls (Figure 3.4). This implies that mast cells may survive conditioning and retain one
of their primary functions, cellular degranulation, lending credence to the idea that
recipient-derived mast cells could be present and active during onset of cGVHD.
To move this study in vivo, we began by examining what models would be available
to us. The lab of Steve Galli, a world leader in the biology of mast cells, had deposited at
Jackson Labs a strain of mast cell-deficient mice derived from the C57BL/6 mouse106.
While C57BL/6 are used for many models of aGVHD, there is only one model of cGVHD
which would allow us to use these mice. The LP/J  C57BL/6 model of cGVHD is,
serendipitously, a model characterized by progressive and systemic dermal sclerosis53; we
have already seen evidence that mast cells may be involved in such processes. Based on
previous work and our preliminary data demonstrating mast cell survival, we opted to
examine the role of recipient-mast cells in cGVHD onset.
To better fit into the previous literature, this transplant solely used 8.5Gy TBI for
conditioning, as had been previously reported34. As shown in Figure 4.1, there would be
three groups: a C57BL/6  C57BL/6 syngeneic transplant which would serve as a negative
control for disease progression, a LP/J  C57BL/6 allogeneic transplant (allo-WT), and a
LP/J  C57BL/6 MC-deficient animals, our experimental group (allo-MCd). Mice would
be analyzed upon either reaching morbidity due to cGVHD or after 7 weeks.
After this transplant was performed, a striking clinical phenotype became apparent,
as the allo-MCd group was developing significantly less cGVHD symptomology. 3 mice
in the allo-WT group had to be euthanized due to morbidity, while none developed severe
disease in the allo-MCd animals (Figure 4.2A). Further, a whole-animal GVHD scoring
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system showed a large reduction in overall scoring after transplant in the allo-MCd animals
(Figure 4.2B). After the 7-week timepoint, tissues from the mice were scored by a blinded
pathologist and it was found that only the skin of allo-WT animals developed significant
GVHD characteristics, while allo-MCd and syngeneic animals were not significantly
different.
A classical feature of dermal cGVHD is skin thickening, especially due to
significant collagen deposition in the dermal layer. We therefore examined the dermis of
these mice by Masson’s trichrome staining which stains collagen a deep blue. A thin,
diffuse, and well-ordered layer of collagen was visible in the syngeneic and allo-MCd
animals, while the allo-WT animals had a much thicker and denser layer of collagen
(Figure 4.4).
Taken together, these symptoms demonstrate several things: first, we were able to
recapitulate the sclerodermatous cGVHD symptomology (whole animal disease, skin
thickening and lesioning) for which the LP/J  C57BL/6 model is known. Second, these
symptoms were significantly ameliorated in the allo-MCd animals. While our hypothesis
anticipated this, the difference between allogeneic groups was nonetheless striking,
especially as cGVHD is considered to be so multifactorial. Lastly, it became increasingly
clear that while mast cells may be critical in initiating cGVHD, at least in this model
system, we would need to establish a mechanism by which this took place. While mast
cells had not previously been implicated in cGVHD pathogenesis, a known mechanism
would allow us to examine the presence or absence of possible mast cell contribution in
disparate murine and human models.
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To that end, we took a broader approach to our analysis. Nanostring analysis on the
skin of mice across all three groups demonstrated striking differences in genes associated
with fibrosis (Figure 4.5). Mast cells were also activated in the allo-WT animals (Figure
4.6). The juxtaposition of these two factors led us to wonder whether mast cells could have
a direct effect on dermal fibroblast populations. When we cultured murine skin-derived
fibroblasts with supernatants from quiescent or activated mast cells, the supernatants from
activated cells significantly increased fibroblast proliferation (Figure 4.7). As has been
mentioned, Levi-Schaffer had previously reported that cGVHD fibroblasts could stimulate
mast cell proliferation; now we see the corollary. This evidences a possible mast
cell/fibroblast feedback loop in cGVHD. Because of this, in patients with dermal cGVHD,
I would expect to see mast cell infiltrates alongside significant collagen deposition, even
as many other inflammatory cells may be sparse.
We therefore examined skin biopsies from patients with dermal cGVHD who had
undergone transplant at the UK Markey Cancer Center. They displayed characteristic
features of cGVHD, including skin thickening and a scattered and diffuse immune cell
infiltrate when examined by H+E staining. When stained for tryptase, a mast cell marker,
patients with cGVHD had a significant increase in dermal mast cells as compared to
healthy controls (Figure 4.8). Of course, while any retrospective clinical study is correlative
in nature, this does lend credence to mast cells being involved in human, as well as murine,
cGVHD.
Both acute and chronic GVHD are, at some level, initiated or maintained through
infiltration of immune cells and inflammation. This immune infiltration can often be
secondary to dysregulated cytokine and chemokine signaling in the tissues that leads to
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recruitment of these inflammatory cells, which subsequently become activated and cause
the tissue damage seen in GVHD. In particular, CCL5 is known to be critical in aGVHD68,
while CXCL10 is the most consistent biomarker seen in cGVHD studies35.
However, it is largely unknown as to which cell type produces the chemokines
involved in this inflammatory cascade. While some specific examples have been
discovered, such as the role of donor-derived T-cells in CCL5 production68, oftentimes it
is assumed to be tissue resident cells, such as macrophages, that produce these factors.
However, there is substantial evidence that both human and murine mast cells may be
capable of producing a huge variety of chemokines and cytokines, depending on the
stimulus, in order to fine-tune the type and degree of inflammatory infiltrate75,131.
Therefore, we hypothesized that mast cells may be one of the primary producers of
chemokines in the post-transplant environment. Reductions in chemokine levels in the alloMCd mice would allow us to see both primary production of chemokines by mast cells, as
well as the secondary effects that a lack of mast cells has on the tissue microenvironment.
Therefore, we reexamined our NanoString data to look for broad trends in the data.
We performed PANTHER pathway analysis to examine the skin for types of cellular
processes that may be upregulated. When we analyzed the sets of genes that were
differentially expressed between allo-MCd and allo-WT skin, only one pathway was
significantly different; inflammation mediated by chemokine and cytokine signaling. A
heatmap of the genes involved in chemokine signaling pathways is shown in Figure 5.1.
As you can see, the allo-WT group had significant upregulation of these pathways, while
the syngeneic and allo-MCd groups did not. Additionally, when we examined several of
the most differentially expressed genes in this pathway, we saw genes coding for CCL2,
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CCL3, CCL4, and CCL5 were all significantly higher in allo-WT animals than other groups
(Figure 5.2A). Since transcript-level analysis does not always track with protein
expression, we also measured protein levels of these chemokines, finding the exact same
trend as with transcript (Figure 5.2B).
Chemokine expression in this context is not necessarily meaningful unless it
correlates with clinical outcome. Therefore, we analyzed expression levels of each of these
chemokines alongside the GVHD score of individual mice and saw that there was excellent
correlation between the two (Figure 5.3). While correlation does not imply causation, it is
nonetheless interesting that all levels of all 4 chemokines tracked so well with wholeanimal GVHD scoring. There was also an evident increase in dermal immune infiltrate in
allo-WT animals (Figure 5.4) which was primarily lymphocytic in nature (Figure 5.5).
Indeed, T-cells and markers of T-cell activation were also significantly higher in allo-WT
animals (Figure 5.6). Importantly, all of these changes were ameliorated in the allo-MCd
animals, indicating that mast cell responses are critical for GVHD.
However, despite these changes, we do not know whether mast cells are directly or
indirectly responsible. Given the mast cell-dependent nature of chemokine upregulation in
the skin, we decided to examine mast cells ex vivo for their capacity to produce these
chemokines. Additionally, we also drugged mast cells with compounds used clinically in
the treatment of steroid-refractory cGVHD, ibrutinib and ruxolitinib. Mast cells produced
high levels of CCL2, CCL3, and CCL4 upon activation with IgE with or without IL-33,
production of which was blocked in a dose-dependent manner by either ibrutinib or
ruxolitinib (Figures 5.8, 5.9).
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What these data show, particularly in the allo-WT mice, is a classic example of
cGVHD symptomology. After BMT, the mice in this model are known to develop
scleroderma, and a chemokine-driven diffuse inflammatory cell infiltrate. The novelty is
in the addition of the allo-MCd group, which as we showed, does not develop many of the
same characteristics. Not only do the animals get less sick and fewer dermal manifestations,
but chemokine production is significantly and specifically decreased. Additionally,
immune infiltrate is not significantly different than in a syngeneic transplant. What we can
take away from this experiment is a confidence that mast cells are crucial mediators for
fibrosis and effector cell recruitment in this context.
Additionally, this allows us some insight into mechanisms by which GVHD could
be further lessened. Ibrutinib is FDA-approved for treatment of steroid-refractory
cGVHD121, and ruxolitinib has recently finished its Phase 3 trial for the same indication,
meeting both primary and secondary endpoints72. These drugs are potentially gamechanging in treatment and management of cGVHD. Our data demonstrating that mast cells
produce many of the same chemokines seen to be significantly upregulated after allogeneic
transplant allows for modulation of mast cell activity. Mast cells use the ibrutinib and
ruxolitinib target proteins (BTK/ITK and Jak1/Jak2, respectively) as key mediators in
cytokine signal transduction and downstream of FCeR1a.Therefore, while these studies did
not address the mechanism by which mast cells are being activated in cGVHD, these drugs
block many of the key signaling pathways.
Indeed, several studies have shown that mast cells are amenable to inhibition with
these molecules in other contexts132–134. There is no reason to believe that mast cell
activation in the context of cGVHD would not be similarly inhibited by these compounds.
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Given that we see a dose-dependent reduction in chemokine signaling with both ibrutinib
and ruxolitinib, we propose that their inhibition of mast cell activation and chemokine
production may be key mechanisms by which these drugs are clinically efficacious.
While we have shown that cGVHD development in this model is mast celldependent, we have not addressed one of our initial questions; are these mast cells derived
from donor or recipient? Even if there was a theoretically perfect drug to inhibit mast cell
activity, the kinetics of dosing would be dependent on the mast cell origin. Leveson-Gower
showed that mast cells can be beneficial in some contexts, and so complete inhibition
would likely be detrimental.
We therefore stained for mast cells in the tissues after transplant. It was
immediately clear that mast cells were still present in the syngeneic and allo-WT groups,
but that the allo-MCd animals remained almost entirely mast cell-deficient across multiple
tissues (Figure 6.1, 6.2). To confirm this striking observation, we stained with avidin,
which selectively binds to mast cell granules. Again, we saw that no mast cells were present
in the allo-MCd animals (Figure 6.3). Additionally, levels of mast cell-specific genes in
the skin were extremely low (Figure 6.4). What this tells us is that in this transplant, the
mast cells in the syngeneic and allo-WT groups were likely recipient-derived. If donor mast
cells had reconstituted from the marrow, we would have also seen the presence of mast
cells in the allo-MCd animals; while they are genetically incapable of producing mast cells,
they are perfectly capable of supporting mast cell growth and survival if they are engrafted
into the mouse106.
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However, while this is logical, it is insufficiently rigorous to completely answer the
question of donor-vs.-recipient origin. Therefore, we designed a separate transplant in
which marrow and splenocytes from MCd mice would be injected into WT C57BL/6 mice
after either TBI or chemotherapy-based conditioning (Figure 6.5). In this way, since the
marrow would be incapable of producing new mast cells, any mast cells in the tissues must
be recipient-derived, having survived conditioning and the post-transplant environment.
After transplanting the mice, analysis was performed 60, 90, and 120 days later.
When stained with avidin (Figure 6.6) or toluidine blue (Figure 6.7A), mast cells were
slightly reduced, though still present after 60, 90, or 120 days in groups that had undergone
either chemotherapeutic or TBI-based conditioning. Confirming that both mast cell stains
worked well and were staining the same cells, we examined each mouse for correlation
between the two methods (Figure 6.7B). Representative images of mice at day 120 are
shown in Figure 6.8 and show that mast cells were still present at this timepoint.
This is the first direct evidence of recipient-derived mast cell survival after
transplant. Mast cell survival out to 120 days was surprising and remarkable; even as it is
known that mast cells are long-lived. For many mice, 120 days may be a significant portion
of the total lifespan of the organism, adding further credence to the “long-lived” mast cell
moniker.
However, there is much work left to do and many questions still to ask in this field.
To begin with, I would like to address some potential shortcomings or issues with our
approach in these studies. The B6.Cg-KitW-sh/HNihrJaeBsmGlliJ mast cell-deficient mice
ae well characterized and have been used to model the role of mast cells across many
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diseases. However, strictly isolating the role of mast cells using this model can be
problematic due to the nature of the genetic changes in this model that allow for mast celldeficiency. Most murine models of mast cell-deficiency are based around disruptions of
the Kit gene, but this particular model has a genetic inversion covering several dozen genes,
including some that are involved in immune function135,136. This can therefore lead to a
false signal if one of the other genes is critical for disease processes independent of mast
cells137.
This raises another point; while we have amassed a significant amount of data on
the effects of mast cell-deficiency in GVHD, much of it could be attributed to secondary
effects. This could be, as mentioned, due to genetic factors involved in the Kit inversion.
Another possibility is that while mast cells seem to be involved in creating a proinflammatory environment early on in the disease pathogenesis, they may be less critical
once an inflammatory infiltrate is established. Therefore, once present in the tissues, more
canonical GVHD effector cells such as neutrophils or T-cells may be capable of driving
the disease even in the absence of mast cells.
These pitfalls are important for the future research direction of our lab, and more
broadly, the GVHD field. To begin with, addressing the issue of the Kit inversion is
relatively straightforward. Several labs have developed murine models of Kit-independent
mast cell-deficiency across multiple genetic backgrounds138–140. These include both
constitutive and inducible mast cell knockouts, most commonly involving the Cpa3 gene
which is critical for mast cell development and function. While not received in time to use
in my studies, the lab of Hans Reimer-Rodewald has a Cpa3 model of mast cell-deficiency
on the Balb/C background138, which would allow us to use a second model of
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sclerodermatous cGVHD, the B10.D2  Balb/C model. Other mouse models have
genetically encoded tagging proteins under the Cpa3 mast cell promoter, allowing for easy
identification, tagging, or removal of mast cells from the tissues in order for single cell
analysis. Studies using these models would add significant rigor and specificity to our
current data.
Another area of interest for future studies would be to determine the mechanism of
activation of mast cells in the post-transplant environment. As has been discussed, the main
methods of mast cell activation are via IgE or IL-33 signaling. Therefore, we plan to use
transgenic mouse models of FCeR1a, IL-33, or ST2 (the IL-33 receptor) deficiency which
will be provided to us by our collaborators at the University of Pittsburgh. When used in
the LP/J  C57BL/6 model of cGVHD, we will be able to determine whether mast cell
activation is regulated by either or both of these molecules. This could allow for more
precise targeting of mast cell function, especially in conjunction with pharmaceutical
intervention.
Indeed, while therapeutic targeting of mast cells is difficult due to the nonspecificity of most drugs that affect mast cell responses (such as cromolyn sodium,
ibrutinib, and ruxolitinib), we are developing mechanisms by which individual mast cells
can be isolated after treatment in order to determine their phenotype. We are also in talks
with a pharmaceutical company to initiate a Phase I clinical trial to examine a proprietary
mast cell inhibitor in the context of cGVHD. These studies will allow us to determine
mechanisms of mast cell activation and possible therapeutic interventions by which they
may be targeted for the treatment or prevention of cGVHD. This is demonstrated in Figure
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7.1, where we show the mechanisms by which mast cells induce cGVHD in our model, as
well as possible pathways that could be targeted for therapeutic intervention.
Lastly, we have a study in progress aiming to determine the donor-vs.-recipient
origin of mast cells in the context of an allogeneic transplant. This utilizes mice with
CD45.1+ recipients vs. CD45.2 donors. Therefore, this will allow us to determine immune
chimerism, as well as the kinetics of tissue mast cell replacement from the marrow. This
will allow for significant insight into the dynamics of mast cell activation, killing by
alloreactive cells, and replacement from the marrow in the post-allogeneic transplant
environment.
Ultimately, these studies are only a beginning. While we show that many of the
features of murine chronic GVHD are dependent on mast cells, this work raises many
questions in regard to their mechanism of activation, their survival after allogeneic
transplant, and their normal physiological roles. While the mast cell, particularly in the
context of allergy, is viewed as relatively one-dimensional, these studies put the lie to that
paradigm.
In summary, this dissertation shows that mast cells are viable and capable of
maintaining their functional capabilities after irradiation. Chemotherapeutic regimens
similar to those used in pre-transplant conditioning also had no effect on cell count or
viability. We show that in vivo, cGVHD-related complications of allogeneic transplant,
including skin fibrosis and effector cell recruitment, are minimized in MC-deficient mice,
and that human patients with dermal cGVHD have increased mast cell numbers in the skin.
We show that mast cells are regulated by drugs currently used in treatment of cGVHD, and
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that in vivo, recipient-derived mast cells are not eliminated by conditioning or the posttransplant environment. Lastly, we establish a framework of future experiments which
could lead to more specific and targetable therapeutic intervention for mast cells in
cGVHD.
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Figure 7.1: Targetable pathways of mast cell-mediated propagation of cGVHD
We have shown that mast cells are involved in the propagation of dermal cGVHD. These
mast cells survive conditioning and induce cGVHD symptomology through their
interactions with fibroblasts and their recruitment of alloreactive immune effector cells.
We here show these pathways and means by which they may be therapeutically targeted.
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LIST OF ABBREVIATIONS
AEU

Allergic Effector Unit

aGVHD

Acute Graft-versus-Host Disease

Allo-HSCT

Allogeneic Hematopoietic Stem Cell Transplant

Allo-MCd

Allogeneic - Mast Cell-Deficient

Allo-WT

Allogeneic - Wild Type

AML

Acute Myeloid Leukemia

APC

Antigen Presenting Cell

ATP

Adenosine Triphosphate

BD

Becton-Dickinson

bFGF

Basic Fibroblast Growth Factor

BM

Bone Marrow

BOS

Bronchiolitis Obliterans Syndrome

BPTP SRF

Biospecimen Procurement and Translational
Pathology Shared Resource Facility

BTK

Bruton's Tyrosine Kinase

Bu-Cy

Busulfan/Cyclophosphamide

CD

Cluster of Differentiation

cGVHD

Chronic Graft-versus-Host Disease

CML

Chronic Myeloid Leukemia

CO2

Carbon Dioxide

DAMP

Danger-Associated Molecular Pattern

DCs

Dendritic Cells

DHHS

Department of Health and Human Services
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DMEM

Dulbecco's Modified Eagle's Medium

DMSO

Dimethyl Sulfoxide

DNA

Deoxyribonucleic Acid

DNP

Dinitrophenol

FCeR1a

FC Epsilon Receptor 1a

FDA

Food and Drug Administration

GC

Germinal Center

G-CSF

Granulocyte Colony Stimulating Factor

GI

Gastrointestinal

GVHD

Graft-versus-Host Disease

GVL

Graft-versus-Leukemia

Gy

Gray (unit of radiation)

H+E

Hematoxylin and Eosin

HLA

Human Leukocyte Antigen

HSCT

Hematopoietic Stem Cell Transplant

IACUC

Institutional Animal Care and Use Committee

IFN

Interferon

IFNgamma

Interferon Gamma

IgE

Immunoglobulin E

IHC

Immunohistochemistry

IL

Interleukin

IRB

Institutional Review Board

Jak

Janus Kinase

MCd

Mast Cell-Deficient
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MCs

Mast Cells

MHA

Minor Histocompatibility Antigen

MHC

Major Histocompatibility Complex

MIMG

Microbiology, Immunology, and Molecular Genetics

NK cell

Natural Killer Cell

NMA

Non-myeloablative

PAMP

Pathogen-Associated Molecular Pattern

PANTHER

Protein Analysis Through Evolutionary Relationship
s

qPCR

Quantitative Polymerase Chain Reaction

qRT-PCR

Quantitative Reverse Transcription Polymerase
Chain Reaction

RIC

Reduced-Intensity Conditioning

RNA

Ribonucleic Acid

ROS

Reactive Oxygen Species

RPMI

Roswell Park Memorial Institute Medium

SCF

Stem Cell Factor

TBI

Total Body Irradiation

Tfh

T-follicular Helper

TGF-beta

Transforming Growth Factor Beta

Th

T-helper

TLR

Toll-Like Receptor

TNF-alpha

Tumor Necrosis Factor Alpha

Treg

T-regulatory cell

UK

University of Kentucky
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VEGF

Vascular Endothelial Growth Factor
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